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Human umbilical vein endothelial (HUVE) cells have been 
previously reported to express the genes for the A and B chain 
peptides of the dimeric molecule Platelet-Derived Growth 
Factor (PDGF) and to secrete PDGF-related factors into culture 
media. Anti-human PDGF IgG affinity chromatography was used 
to purify PDGF-related activity from HUVE cell conditioned 
media. Immunoblot analysis of the affinity purified proteins 
with anti-PDGF IgG and antibodies specific for the A or B 
chain peptides of PDGF combined with chemotactic and mitogenic 
assays revealed that the major PDGF immunorelated molecule 
secreted by HUVE cells is a monomer of approximately 36-38 kd 
MW and that less than 15% of the purified biologically active 
molecules are PDGF A or B chain peptides. Screening of an 
HUVE cell eDNA library in the expression vector lambda gtl1 
with the anti-PDGF antibody resulted in the cloning and 
sequencing of a cDNA with an open reading frame encoding a 38 
kd cysteine-rich secreted protein which our data indicate is 
the major PDGF-related mitogen secreted by human vascular 
endothelial cells. The protein has a 45% overall homology to 
the translation product of the v-src-induced CEF-10 mRNA from 
chick embryo fibroblasts. We have termed this mitogen 
Connective Tissue Growth Factor (CTGF). 
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INTRODUCTION 
The peptide growth factors are a diverse group of protein 
hormones which are involved in the migration, proliferation 
and differentiation of various cell types. Growth factors act 
in a paracrine or autocrine fashion by binding to specific 
cell surface receptors on their target cells and mediate their 
biological effects either directly by receptor phosphorylation 
of cytoplasmic proteins or through the activation of 
cytoplasmic second messengers. The result of these mechanisms 
includes kinase activation and protein phosphorylation, 
increase in calcium and other cation concentration, induction 
of transcription of specific genes and translation of proteins 
necessary for progression through the cell cycle. (Pardee, 1989 
for review.) Both growth factors (Waterfield et 
al.,1983;Doolitle et al.,1983) and growth factor receptors 
(Downward et al.,1984;Sherr et al.,1985) are related to 
cellular oncogenes, thereby linking the control of normal 
growth with pathological growth and neoplasia. Clinically, 
a thorough understanding of the peptide growth factors will 
lead to therapies which will augment normal processes such as 
wound healing and inhibit the pathological effects of these 
factors in tumorogenesis and cancer metastasis. 
The growth factors involved in epithelial and mesenchymal 
ca~~ development and regeneration work in concert to cause the 
migration and proliferation of cells in areas needed such as 
epithelia of the skin and gut or in the healing of a wound. 
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Studies done in fibroblasts (stiles et al.,1979) demonstrated 
that stimulation with at least two types of growth factors are 
necessary for cells to enter and progress through the cell 
cycle. Platelet-Derived Growth Factor (PDGF) has been 
described as a competence factor and binding of PDGF to cell 
surface receptors of quiescent fibroblasts causes cells to 
move from the Go stage to the G1 stage of the cell cycle 
(Stiles et al.,1979). The G1 phase is a preparatory, 
biosynthetic stage characterized by protein phosphorylation, 
calcium ion increases, kinase activation and the induction of 
the fos (Greenburg and Ziff,1984) and myc (Kelly et 
al., 1983 iCochran et al,1983) genes, which produce nuclear 
proteins involved in gene regulation. Cells made competent 
by the action of PDGF will remain in the G1 stage and not 
progress further in the cell cycle unless stimulated by a 
progression factor such as Epidermal Growth Factor (EGF) or 
Insulin-like Growth Factor (IGF). These progression factors 
will cause the fibroblasts to enter the S phase of the cycle 
in which DNA is duplicated (Leof,et al.,1982;Leof et 
aI.,19S3). Cells which enter -the S phase will complete the 
cell cycle by progressing through G~ and into the mitotic M 
stage without further external stimulation by growth factors 
or other agents. stimulation with a progression factor first 
and then a competence factor results in cells only entering 
the G1 phase of the cycle. Further stimulation with a 
progression factor is needed to enter the-- S phase. This 
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indicates that certain induced proteins and second messengers 
in the competence stage are necessary for proper responses to 
progression factors and completion of the cell cycle (Stiles 
et ale ,1979). The work with fibroblasts demonstrates that the 
regulation of cellular proliferation is a complex process that 
requires multiple intracellular signals and external stimuli 
to induce entry and completion of the mitotic cycle. 
Therefore, the availability of competence and progression 
factors to target cells in vivo must be optimized in both time 
and place for tissue regeneration and development to occur. 
Investigations into the nature of growth factors have 
determined that there are families of structurally and 
functionally similar molecules which are expressed 
differentially by cells and tissues and this multiplicity 
ensures that the necessary biological activity is present when 
needed. A brief synopsis of these families of factors 
involved in connective tissue growth is instrumental in 
understanding the work we have done with PDGF and growth 
factors biologically related to PDGF. 
Epidermal Growth Factor (EGF) was originally purified 
from mouse salivary glands (Cohen, 1962) and later from human 
urine (Cohen and Carpenter, 1975) and platelets (Oka and 
Orth,1983). The biologically active molecule is a 53 amino 
acid peptide containing three internal disulfide bonds 
(Gregory,1975iTaylor et al. ,1972). EGF is a mitogen for 
epithelial and endothelial cells and fibroblasts. The ligand 
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binds a 170 kd cell surface receptor which is related to the 
erb B oncogene (Downward et al.,1984). A related molecule, 
Transforming Growth Factor alpha (TGF-a) exists in multiple 
species ranging from 5-20 kd with the smallest form being a 
50 amino acid molecule with 30% homology to EGF including 
conservation of the six cysteine residues (Marquardt et 
al.,1984). This sequence homology and formation of the three 
intramolecular disulfide bonds may indicate similar protein 
tertiary structure and explain binding of both EGF and TGF-Q 
to the same cell surface receptor (Massague, 1983) • In 
addition to the EGF and TGF-a peptides, a larger molecule of 
27-30 kd has been identified in human platelets which is 
immunologically related to these two molecules and binds the 
same receptors (Oka and Orth,1983iBowen-pope and Ross,1983). 
Transforming Growth Factor beta (TGF-P) is a 25 kd 
dimeric molecule composed of two identical monomers held 
together by nine disulfide bonds (Derynck et al.,1985). TGF-
~ has been identified in various tissues and purified from 
human platelets (Assoian et al .. , 1983) and human placenta 
(Frolich,et al.,19B3). TGF-p has been shown to be a mitogen 
for a variety of mesenchymal cell types in monolayer culture 
(Shipley et al., 1985; Roberts et al., 1985; Massague, 1984) , 
although further investigation has indicated that this may be 
an indirect effect involving the induction of PDGF related 
molecules (Leaf et al.,19B6;Soma and Grotendorst,1989). TGF-
f3 is an inhibitor of endothelial (Baird> and Durkin, 1986 ; 
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Frater-Schroder et al.,1986; Heimark et al.,1986;Muller et 
al.,19B7; Takahara et al.,19S7) and epithelial cells (Masui 
et al.,1986iTucker et al.,1984) and regulates the 
differentiation of bronchial epithelial and other cell types 
(Masui et al 1986). Two different TGF-p monomers (Beta 1 and 
Beta 2) have been identified and share greater than 70% amino 
acid sequence homology, including conservation of all cysteine 
residues (Cheifetz et al.,19B7). A third monomer (TGF-Beta 
3) has recently been cloned (ten Dijke et al.,1988). 
Fibroblast Growth Factor (FGF) was originally identified 
from extracts of pituitary and brain as an activity which 
stimulated the growth of 3T3 cells (Armelin,1973; 
Gospodarowicz,1974). The biological activity was later shown 
to be due to two proteins, acidic FGF (pI 5. 6) (Maciag, et 
al.,19B4;Thomas,et al.,1984) and basic FGF (pI >9.0) (Esch,et 
ale , 1985) which share a 55% amino acid sequence homology 
(Esch,et al.,1985). A human cDNA clone for acidic FGF (Jaye 
et al.,1986) has been sequenced as has a eDNA clone for basic 
FGF (Abraham et al.,1986) and both messages indicate 155 amino 
acid precursor molecules. The FGF proteins do not have leader 
peptides and therefore are not thought to be secreted 
molecules but are released upon tissue damage and cell 
rupture. These growth factors are mitogenic for cells of 
mesenchymal origin including fibroblasts, endothelial and 
smooth muscle cells, myoblasts and osteoblasts. Fibroblast 
growth factor molecules have been found in most tissues 
6 
examined and range in size from 15,000 to 18,000 MW. Higher 
MW forms have been identified and multiple forms of mRNA 
transcripts detected, suggesting differential protein 
processing and mRNA splicing. Several other proteins have 
been identified which constitute a family of homologous 
proteins with similar biological activities. The FGF-5 
protein is a 267 amino acid molecule with 43% homology to FGF 
which is mitogenic for both fibroblasts and endothelial cells 
(Zhan et al.,1988). The gene product of the hst\K-fgf gene 
is a 206 amino acid protein with similar biological activity 
which also has 43% amino acid homology to FGF and was isolated 
from a Karposi's sarcoma (Delli-Bovi et al.,19S7; Del1i-Bavi 
et al., 1988) . Both the FGF-5 and hst\K-fgf proteins are 
translated with a signal sequence and are secreted into media 
from transfected tissue culture cells. A fifth member of this 
family is the product of the int-2 gene which has a 44% amino 
acid sequence homology to FGF (Dickson and Peters,1987). 
Platelet-Derived Growth Factor (PDGF) has been 
characterized as a mitoattractant due to its chemotactic 
effect on fibroblasts and smooth muscle cells at lower 
concentrations (0.1-1.0 nM) and its mitogenic effect on these 
cells at higher concentrations (0.5-5 nM) (Grotendorst and 
Martin,1986). PDGF has not been shown to be mitogenic on 
epithelial or endothelial cells. PDGF was originally 
identified (Ross et al.,1974;Kohler and Lipton, 1974) and 
purified (Antoniades et al.,1979;Heldin et al.,1979;Heldin et 
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al. , 1981) from the alpha granules of human platelets. 
Platelet PDGF is a dimeric molecule which migrates on SDS-
polyacrylamide gels at approximately 30 kd. Reduction of 
dimeric PDGF yields A chain (17 kd) and B chain (14 kd) 
peptides which share a 60% sequence homology including 
conservation of seven cysteine residues. The gene for the A 
chain is located on chromosome 7 (Bonthron,et al.,1988) and 
the B chain (c-sis) gene on chromosome 22 (Dalla Favera et,al. 
1981). The monomeric peptides are not biologically active as 
a mitogen (Antoniades,1981) or a chemoattractant (Grotendorst 
et al., 1981). The three possible isoforms of PDGF, the AA and 
BB homodimers and the AS heterodimer, are found naturally and 
all are biologically active (Heldin et al.,1986; Betsholtz et 
al.,1985; Stroobant and Waterfield,1984). Two high affinity 
cell surface receptors have been identified and are tyrosine 
kinases (Heldin et al.,1981iGronwald et al.,1988;Hart et 
al.,198S;Heldin et al.,1988). Differential binding of the 
PDGF isoforms to these receptors has been reported with the 
type alpha receptor binding all three isoforms and type beta 
binding only the BB and AB dimers (Bowen-Pope et al.,1989). 
The B chain of PDGF demonstrates sequence homology with the 
v-sis oncogene and may be involved in cell transformation by 
an autocrine mechanism (Doolittle et ale ,1983 ; Robbins et 
al.,1983;Owen et al,1984). Human macrophages activated with 
bacterial endotoxin secrete a PDGF related activity into 
culture media which is neutralized by ~anti-PDGF antibody 
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(Martinet et ale ,1986). Immunoblots of this conditioned media 
with an anti-PDGF antibody indicate that the biological 
activity is produced by a 16 kd monomeric molecule 
antigenically related to PDGF and has been termed Macrophage 
Derived Growth Factor (MDGF) (Pencev and Grotendorst,1988). 
Partial amino acid sequence was obtained for this peptide 
indicates that it is not related to the A or B chain of 
platelet PDGF but is a product of the connective Tissue 
Activating Peptide III gene, which has recently been cloned 
and sequenced (Wenger,et a1.,1989). The biological activity 
may be due to similar conformation of PDGF dimers and the 
monomeric MDGF protein and binding of the macrophage ligand 
to the PDGF cell surface receptor. 
The work presented here with PDGF-related proteins 
secreted by human vascular endothelial cells provides evidence 
of a group of peptides which produce their biological effects 
through the PDGF cell surface receptor probably due to 
conformational similarity of the mature proteins. The brief 
synopsis of growth factors presented above demonstrates that 
the peptide growth factors have evolved into families of 
multiple genes and proteins capable of producing similar 
biological activities. It seems probable then that there are 
other genes and proteins related to PDGF whic~ are chemotactic 
and mitogenic for mesenchymal cells in addition to the 
presently identified PDGF A and B chain peptides. 
Conditioned media from cultures of Human Umbilical Vein 
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Endothelial (HOVE) cells have been reported to contain factors 
which compete with platelet PDGF for binding to the PDGF cell 
surface receptor of fibroblasts and demonstrate PDGF-related 
biological activity (DiCorletto, 1984) • HOVE cells express 
both the A and B chain genes of PDGF (Collins et al.,1985; 
Collins et al.,1987; Doolitle et al.,1987). The B chain gene 
of PDGF produces a single transcript in HUVE cells of 3.8 kb 
(Collins et al., 1985). The HOVE cell PDGF A chain gene is 
expressed as three mRNA transcripts of 2.8,2.3 and 1.7 kb, 
wi th the longest transcript thought to be the only one 
translated (Bonthron et al.,1988). The HUVE A chain mRNA 
differs from A chain transcripts derived from neoplastic 
glioma cell lines by alternative splicing in which exon six 
of the genomic sequence is removed from the HUVE transcript, 
resulting in a translated peptide lacking a highly basic 15 
amino acid carboxy terminal region found in the glioma peptide 
(Collins et al.,1987; Tong et al., 1987). Since both the A 
and B chain genes are expressed, the secreted molecules could 
be AB heterodimers or AA or BB homodimers. The question we 
originally asked was what form of PDGF is secreted by human 
endothelial cells? 
We have investigated the composition and nature of the 
PDGF-related mitoattractant activity secreted by human 
vascular endothelial cells. PDGF-immunoreactive molecules 
were purified from HOVE cell conditioned media by anti-PDGF 
IgG affinity chromatography. Biological- assays of these 
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affinity purified proteins in conjunction with immunoblots 
using sequence specific anti- A and B chain POGF antibodies 
indicate that less than 15% of the PDGF-related molecules 
contain sequences which are antigenically related to PDGF A 
or B chain. The major mitoattractant secreted by these cells 
appears to be a 36 kd molecule which is related to platelet 
PDGF but is not a product of the PDGF A or B chain gene. 
Screening of an expression eDNA library made from the mRNA of 
HOVE cells with anti-PDGF antibody has resulted in the cloning 
and sequencing of a cDNA which encodes a 38 kd peptide which 
our data indicates is the primary source of the PDGF-related 
biological activity secreted by HUVE cells. We have termed 
this new mitogen connective Tissue Growth Factor. 
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RESULTS 
Identification and partial purification of PDGF-related 
mitogenic activity trom HUVE cells. 
The initial studies of the nature of the Platelet-Derived 
Growth Factor related proteins secreted by Human Umbilical 
Vein Endothelial (HOVE) cells were done to determine the 
relative molecular weight of the molecules produced, the 
amount of the proteins secreted by these cells, and their 
specific biological activity. 
Endothelial cells were obtained by collagenase perfusion 
from the veins of fresh human umbilical cords and cultured in 
growth media containing 20% fetal calf serum, basic FGF and 
heparin. The growth media was removed from confluent 
cultures, the cells washed and the growth media replaced with 
serum-free media containing no other additives. Aliquots of 
this serum-free media were removed periodically and dialyzed 
against 1 N acetic acid. The proteins were lyophilized, 
resuspended and run on 12% polyacrylamide electrophoresis 
gels. The proteins were electroblotted to nitrocellulose and 
the membranes immunoblotted using anti-PDGF goat IgG as a 
first antibody and rabbit anti-goat IgG alkaline phosphatase 
conjugated as a second antibody. The proteins were visualized 
after incubation with a substrate solution. (Fig. 1). The 
results indicated constitutive secretion of several species 
of molecules which are immunologically similar to human 
platelet PDGF but are of higher molecular weight (36-38 kd) 
12 
Figure 1. 








Figure 1. constitutive secretion of PDGF-immunoreactive 
factors by HOVE cells. 
HOVE cells were grown to confluence in 6 well plates. The 
growth media was removed, cells washed with PBS and 1 ml of 
serum free media was added to each well. The media was 
removed after conditioning for the period of time indicated 
(hours), dialyzed against 1 N acetic acid and lyophilized. 
The samples were then run on 12% PAGE, electroblotted to 
nitrocellulose and visualized with the anti-human PDGF 
antibody. 
Five nanograms of purified platelet PDGF was run as reference. 
positions of MW markers (BioRad) is indicated at right. 
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than the expected 30-32 kd of platelet PDGF or the PDGF A or 
B chain homodimers. The concentration of the proteins in the 
media increases with time, indicating that the proteins are 
being produced by the cells. The anti-PDGF antibody used in 
these experiments was made by immunizing a goat with PDGF 
purified to homogeneity from human platelets (Grotendorst, 
1984). The amino acid composition of the antigen was obtained 
and was consistent with human platelet PDGF and a single band 
was observed on silver stained polyacrylamide gels. This 
antibody does not cross-react with other growth factors such 
as TGF-p, FGF or EGF in immunoblot analysis and is able to 
detect less than 500 picograms of dimeric PDGF molecules or 
10 nanograms of reduced, monomeric A or B chain peptides on 
immunoblots. 
The biological activity of the serum-free conditioned 
media was analyzed by mitogenic and chemotactic assays. These 
results indicated biological activity in the conditioned media 
equivalent to 15 ng/ml of platelet PDGF after 48 hours 
conditioning time (Fig. 2). The activity is comparable to 
platelet PDGF in that it is both chemotactic and mitogenic for 
the fibroblasts used as target cells. Prior incubation of the 
conditioned media with 60 ~g/ml of anti-human PDGF IgG 
neutralized approximately 30% of the mitogenic and chemotactic 
activities. This is in agreement with previous reports 
(DiCorletto,1984). The mitogenic activity remaining after 
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Chemotactic and mitogenic assays of HUVE cell 
conditioned media and affinity purified PDGF immunoreactive 
factors. 
A. Mitogenic assay performed as described using NRK cells 
as target cells. PDGF BB is 5 ng/ml. PDGF AA is 10 ng/ml. 
HUVE media is 250 J'l of HUVE cell serum-free conditioned media 
(48 hrs) which was dialyzed against 1 N acetic acid, 
lyophilized, and resuspended in DMEM before addition to test 
wells. Affinity purified fraction is 5 ~l/ml of combined, 
concentrated major pool from Affi-Gel 10 affinity column. 
Anti-PDGF IgG or non-Immune IgG (30 ~g/ml) was added to the 
samples and incubated 18 hrs at 4°C prior to testing in the 
mitogenic assay. The data points in A and B are the mean of 
triplicte samples with a standard deviation of less than 5%. 
The experiments were repeated at least three times with 
similar results. 
B. Chemotactic assays were performed as described using 
3T3 cells as target cells. PDGF BB is 5 ngjml. PDGF AA is 
10 ngjml. HUVE media is serum-free DMEM, 0.2 mg/ml BSA, 
conditioned for 48 hrs. Affinity purified fraction is 2.5 
J.Lljml of combined, concentrated major pool from Affi-Gel 
affinity column. Antibody neutralization is performed as 
described under A. 
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probably due to FGF and the remaining chemotactic activity to 
fibronectin, both of which are secretory products of 
endothelial cells. In these assays and throughout this 
project, bacterially produced recombinant PDGF AB, AA and BB 
dimeric molecules are used as control standards. These 
molecules offer the advantage of being homogeneously pure, 
wi th no chance of contamination by other growth factors 
present in human platelets (e.g. TGF-p,TGF-a). In biological 
assays conducted periodically in our lab, these recombinant 
molecules produce activities identical to the purified 
naturally occuring isoforms of PDGF. 
The presence in the HUVE cell conditioned media of 
several species of PDGF immunoreactive molecules was 
unexpected, particularly molecules of higher molecular weight 
than those of the A and B chain dimeric molecules anticipated 
to be produced and secreted by endothelial cells (Collins et 
al.,1987;Sitaras et al.,19B7). In similar work previously 
done, we had shown that the non-transformed BSC-l monkey 
kidney epithelial cell line constitutively secretes PDGF-like 
activity into culture media and that 90% of the activity is 
neutralized by anti-PDGF IgG. Immunoblots of the dialyzed 
media proteins using the anti-PDGF antibody indicated a single 
band which co-migrated on polyacrylamide gels with the PDGF 
BB homodimer. This was consistent with the production of PDGF 
B chain mRNA but no A chain mRNA in these cells (Kartha et 
al.,1988). 
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In order to obtain greater amounts of the PDGF-like 
proteins for further analysis, the HOVE cells had to be kept 
in media containing 20% fetal calf serum, since these cells 
begin to die after 24 hours in serum-free or low serum media. 
The PDGF immunoreactive proteins were partially purified from 
the serum containing media by use of an antibody affinity 
column made with the anti-human PDGF IgG and an Affi-Gel 10 
support (BioRad). When aliquots of the partially purified 
proteins were assayed for chemotactic and mitogenic activity, 
all biological activity could be neutralized by prior 
incubation of the proteins with the anti-human PDGF antibody 
(Fig. 2). This indicated that the only biologically active 
molecules present in the partially purified media proteins 
were PDGF immunorelated molecules. Aliquots of the partially 
purified proteins were immunoblatted using the same anti-PDGF 
antibody and the data indicated the presence of both the 
higher MW molecules observed in the serum-free conditioned 
media and immunoreactive proteins in the 30-32 kd range 
(Fig.3). The major species secreted migrated at 36 kd on 
acrylamide gels and represented at least 50% of the total 
immunoreactive protein. The peptides which comigrated with 
purified platelet PDGF and synthetic A and B chain dimeric 
standards represented less than 15% of the total 
immunoreactive protein. 
purified PDGF blocked 
Prior incubation of the antibody with 
antibody binding to all of the 
molecules, indicating shared antigenic determinants with 
Figure 3. 






Figure 3 . Immunoblot of HUVE cell secreted PDGF-related 
factors. 
Proteins were run on a 12% polyacrylamide gel 
electroblotted to a nitrocellulose membrane and the 
immunoreactive factors visualized with anti-human PDGF IgG as 
described under Experimental Procedures. Lane 1 , 5 J.l.l of 
affinity purified HUVE cell secreted proteins. Lane 2, 10 ng 
of synthetic AA homodimer (top band) and 10 ng of BB homodimer 
(lower band). Lane 3, 50 J.l.l of reduced HUVE affinity purified 
proteins. Lane 4, 5 J.l.l of HUVE affinity purified HUVE 
proteins but with anti-human PDGF antibody blocked with 300 
ng of PDGF. Lane 5, Control column of 10 J.l.l of anti-PDGF 
Affi-Gel 10 affinity purified protein fraction from media 
which was not conditioned by cells. 
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dimeric platelet PDGF (Fig.3,lane 4). In order to insure that 
none of the antibody binding molecules detected on immunoblots 
was derived from fetal calf serum or other additives in the 
culture media, a new, unused antibody affinity column was made 
and media which was never conditioned by cells was incubated 
at 37 C for two days and processed exactly as the conditioned 
media. No PDGF-immunoreactive molecules were detected in the 
fractions from this column by immunoblot (Fig. 3,lane 5) and 
no biological activity was detected (data not shown). 
When platelet PDGF or the recombinant dimers were reduced 
with 100 roM dithiothreitol and boiled for 5 minutes in the 
presence of SDS, monomeric A chain (17 kd) and B chain (14 kd) 
peptides were observed on immunoblots. Treating the HUVE 
molecules in 100 mM DTT sample buffer and boiling for 5 
minutes resulted in slower migration of the major portion of 
the immunoreactive molecules on polyacrylamide gels (Fig. 3). 
Most of the immunoreactive molecules migrated at 38-39 kd and 
less intense bands were observed at 25 kd and 14 kd. It is 
necessary to run at least 10 times as much reduced protein as 
non reduced in order to detect the reduced proteins. This is 
consistent with the affinity of our antibody for monomeric 
forms of the PDGF A and B chain peptides. Since our antibody 
was produced against dimeric platelet PDGF, a lower affinity 
to monomeric forms is not unexpected. 
Our preliminary data indicated that HUVE cells 
constitutively secrete several molecules ~ which share some 
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antigenic properties with human platelet PDGF and exhibit 
similar biological activities. lnununoblotting procedures with 
both non-reduced and reduced affinity purified protein samples 
indicated that the major immunoreactive protein in the 
biologically active samples was a monomeric molecule which 
migrated at approximately 38 kd. 
In addition to these peptides which constitute the major 
portion of the PDGF immunoreactive molecules, species which 
migrated at higher MW were observed in the first few fractions 
eluted from the anti-PDGF affinity column. In order to 
determine which of all these bands on the immunoblots were 
PDGF-specific, and possibly which were A or B chain related, 
a protein mixture was made by taking an aliquot of each of the 
fractions eluted from the anti-PDGF IgG affinity column used 
to purify these proteins from HUVE cell conditioned media. 
An immunoblot was made with four aliquots of this mixture and 
the membrane was cut into four sections and a section 
incubated with anti-PDGF IgG previously blocked with one of 
the three isoforms of PDGF and one section with unblocked 
antibody (Fig. 4). We found that each of the different 
isoforms of PDGF block binding of the antibody to the major 
secretory products of the endothelial cells to an equal 
degree. The higher molecular weight proteins were unaffected 
by the antibody blocking and are probably due to nonspecific 
binding of the antibody. The PDGF isoforms also block 
antibody binding to each other (i.e. AA dimers block binding 
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Figure 4. Immunoblot of affinity purified HOVE proteins 
demonstrating anti-PDGF antibody blocking with the isoforms 
of PDGF. 
Lanes 1 and 2 anti-PDGF antibody previously incubated 
with recombinant PDGF AA homodimer. Lane 1 contains 1 ~l 
aliquot of HOVE affinity purified proteins. Lane 2 contains 
20 nanograms of PDGF AA homodimer. 
Lanes 3 and 4, anti-PDGF antibody previously incubated 
with recombinant PDGF AB heterodimer. Lane 3 contains 1 ~l 
aliquot of HOVE affinity purified proteins. Lane 4 contains 
10 nanograms of PDGF AB heterodimer. 
Lanes 5 and 6, anti-PDGF antibody previously incubated 
with recombinant PDGF BB homodimer. Lane 5 contains 1 ~l 
aliquot of HOVE affinity purified proteins. Lane 6 contains 
10 nanograms of PDGF BB homodimer. 
Lanes 7 and 8, anti-PDGF antibody. Lane 7 contains 1 ~l 
aliquot of HOVE affinity purified proteins. Lane 8 contains 
10 nanograms of PDGF AB heterodimer. 
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to BB dimers). Therefore, the major IgG clones in this 
polyclonal antibody appear to be against similar epitopes on 
the PDGF isoforms and the endothelial cell molecules. 
From this data alone we were not able to determine which 
of the peptides in the nonreduced lane corresponded to the 38 
kd peptide in the reduced samples, representing the majority 
of the immunoreactive protein, and which produced the 25 and 
14 kd peptides on our immunoblots. In order to analyze this, 
we labeled cultures of HUVE cells with 35s - cysteine and 
affinity purified the anti-PDGF immunoreactive peptides from 
the conditioned media. Equal aliquots of the labeled affinity 
purified proteins were run both reduced and non-reduced on 
polyacrylamide gels and electroblotted to nitrocellulose and 
the membrane processed as for immunoblots using the anti-PDGF 
antibody. The immunoblots were then autoradiographed (Fig.5). 
Transmission scanning of the lanes of the autoradiograph 
determined that the 36 kd band in the nonreduced lane and the 
38 kd band in the reduced lane have equivalent intensity. 
This indicates that the 36 kd molecule is monomeric and shifts 
to the apparent higher molecular weight due to unfolding of 
the molecule upon reduction of intramolecular disulfide bonds. 
There was still a question as to whether these higher 
molecular weight PDGF immunorelated proteins CQuld be 
monomeric precursor forms of PDGF A or B chain peptides which 
were being secreted by endothelial cells without being 












Figure 5. Autoradioqraph and immunoblot of 35s - cysteine 
labeled HUVE cell secreted proteins. 
Confluent cultures of HUVE cells were labeled for 22 
hours in cysteine-free DMEM containing 250 ~Ci/ml of 35S_ 
cysteine. The labeled PDGF-inununoreactive proteins were 
affinity purified from the conditioned media and equal 
aliquots of the proteins run on 12% polyacrylamide gels. The 
proteins were electroblotted to nitrocellulose and the 
membranes processed as for immunoblots. The immunoblots were 
then autoradiographed. 
Side A is autoradiograph of immunoblot shown on Side B. 
Lane 1. 10 ~l aliquot of labeled affinity purified 
proteins,nonreduced. 
Lane 2. 10 ~l aliquot of labeled affinity purified 
proteins,reduced. 
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the case for other cell types studied (Kartha et al.,1988). 
Since the RNA message for both the A and B chains of PDGF is 
expressed in HOVE cells, we wanted to determine which of the 
immunorelated molecules were A chain or B chain peptides and 
which, if any, were not products of the A or B chain genes. 
We have produced a series of antibodies in goats to 
synthetic peptides of 30 amino acid length which represent 
sequences in the amino and carboxy terminal regions of the 
processed PDGF A and B chain peptides. These antibodies are 
specific for the reduced, monomeric A and B chain peptides and 
do not cross react when tested on immunoblots with the reduced 
recombinant AA, SB and AB dimers. The peptide antibodies used 
in these experiments are specific for the amino (residues 79-
107) and carboxy (residues 161-189) ends of the mature 
processed B chain peptide of platelet PDGF and the amino end 
of the processed A chain molecule (residues 92-119) and the 
carboxy end of the short (endothelial) form of the A chain 
molecule (residues 167-193 + DVR; Collins et al. , 1987). When 
100 nanograms of the affinity purified HOVE cell PDGF-like 
proteins are reduced and immunoblotted using the anti amino 
terminal A chain antibody, we detect a single band of peptides 
at 17 kd (Fig. 6). comparison with 10 nanograms of reduced 
recombinant A chain peptides on the same immunoblot indicates 
that only 10 nanograms of proteins containing the amino 
terminal sequence are present in 100 nanograms of HUVE cell 
molecules. Similar results were obtained using the antibody 
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Figure 6. Immunoblot of HOVE cell secreted proteins using A 
and B chain peptide antibodies. 
A. Primary antibody is anti-human POGF IgG. Lane 1, 10 
ng of HOVE affinity purified media proteins, non-reduced. Lane 
2, 100 ng of HOVE affinity purified proteins, reduced. 
B. Primary antibody is anti amino terminal A chain serum 
for lanes 1 and 2 and the antibody blocked with the peptide 
antigen for lanes 3 and 4. Lanes 1 and 3 100 ng of HUVE 
purified media protein, reduced. Lanes 2 and 4, 10 ng of AA 
short form homodimer, reduced. 
c. Primary antibody is anti carboxy terminal A chain 
serum for lanes 1 and 2 and the antibody blocked with the 
peptide antigen for lanes 3 and 4. Lanes 1 and 3, 100 ng of 
HOVE purified media proteins, reduced. Lanes 2 and 4, 10 ng 
of AA homodimer, reduced. 
D. Primary antibody is anti amino terminal B chain serum 
for lanes 1 and 2 and the antibody blocked with the peptide 
antigen for lanes 3 and 4. Lanes 1 and 3 and 200 ng of HOVE 
purified media proteins, reduced. Lanes 2 and 4 are 20 ng of 
BB homodimer, reduced. 
E. Primary antibody is anti carboxy terminal B chain 
serum for lanes 1 and 2 and the antibody blocked with the 
peptide antigen for lanes 3 and 4. Lanes 1 and 3, 100 ng of 
HOVE purified media proteins, reduced. Lanes 2 and 4 are 20 
ng of BB homodimer, reduced. 
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specific for the carboxy terminal of the PDGF A chain (Fig. 
6). The data from these two antibodies indicated that of the 
total PDGF immunorelated molecules secreted by HUVE cells, 
only about 10% contained sequences found in the PDGF A chain 
amino or carboxy terminal regions. The antibody specific for 
the 30 amino acid sequence in the amino terminal of the PDGF 
B chain peptide did not detect any molecules in 200 nanograms 
of reduced endothelial cell proteins. This antibody is our 
least sensitive and it may be that we are not able to detect 
the small amount of PDGF B chain molecules present. The B 
chain carboxy terminal peptide antibody detects reduced 
molecules at 25 kd and at 14 kd in 100 nanograms of HUVE cell 
proteins. Comparison with 20 nanograms of reduced BB 
homodimer run as a standard on the same blot indicates that 
about 5% of the endothelial cell PDGF related molecules 
contain PDGF B chain amino acid sequences. The 14 kd molecule 
is probably reduced B chain which has been proteolytically 
processed. The 25 kd molecule may be reduced 50 kd B chain 
precursor molecule, a small amount of which is found in the 
conditioned media. These data indicate that approximately 
15% of the PDGF immunoreactive molecules secreted by HOVE 
cells contain sequences of the mature PDGF A and B chain 
molecules. The remaining 85% of this biologically active 
protein fraction is not related to the PDGF peptides. 
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Major chemotactic and mitoqenic activity is produced by 36 kd 
peptide and not POGP paptides. 
In order to determine if the chemotactic and mitogenic 
activities observed in the partially purified media proteins 
were the result of the proteins containing the PDGF A and B 
chain peptides or were the result of molecules which do not 
contain these sequences, biological assays were performed with 
serial dilutions of the affinity purified media proteins and 
serial dilutions of recombinant PDGF AA and BB homodimers and 
the AB heterodimer. Sufficient quantities of the samples were 
prepared to perform several mitogenic and chemotactic assays 
and immunoblots with aliquots of each dilution. The mitogenic 
activity of the HUVE affinity purified factors observed was 
comparable to the activity elicited by all three recombinant 
PDGF dimers. The chemotactic activity was comparable to the 
AB heterodimer, producing less response than the BB homodimer 
and greater response than the AA homodimer. When the 
biological activity of the samples was compared with 
immunoblots of equivalent amounts of the same samples, no A 
chain nor B chain molecules were detected in the test samples 
(Fig. 7). As an example, at 20 ng/ml of either the 
recombinant PDGF isoforms or the HUVE cell molecules, the 
biological activity elicited from the target cells was at or 
near maximum, but the immunoblot of equal aliquots of these 
same samples show that no PDGF A or B chain peptides were 
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Figure 7. Biological assays and immunoblots of serial 
dilutions of HUVE cell affinity purified media proteins and 
recombinant PDGF standards. 
Mitogenic assay (A) and chemotactic assay (B) performed as 
described with NIH 3T3 cells. The test samples in both 
biological assays and the immunoblot are identical aliquots 
of the same sample. Data points are the mean of three samples 
and the standard deviation is less than 10%. 
Fig. C, Immunoblot A, primary antibody is anti-human 
PDGF IgG. 
Lane 1, 20 ng HUVE purified media proteins. 
Lane 2, 20 ng AB heterodimer. 
Immunoblot B. Primary antibody is anti amino terminal 
A chain serum. 
Lane 1, 20 ng of HOVE purified media proteins, reduced. 
Lane 2, 20 ng AA homodimer, reduced. Lane 3, 1.25 ng 
AA homodimer, reduced. 
Immunoblot C. Primary antibody is anti carboxy terminal 
B chain serum. 
Lane 1, 20 ng HUVE purified media proteins, reduced. 
Lane 2, 20 ng BS homodimer, reduced. 
Lane 3, 2.5 ng BB homodimer, reduced. 
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level on this blot with these peptide antibodies was less than 
1.25 nanograms for A chain peptides and less than 2.5 
nanograms for B chain peptides. As shown above, we estimate 
that of the total fraction of anti-PDGF immunoreactive 
molecules secreted by HUVE cells, less than 15% contain 
sequences of the PDGF A and B chain gene products. This 
being the case, the biological activity produced by the test 
samples in these dilution assays cannot be accounted for by 
PDGF A or B chain containing molecules. These data strongly 
indicated that the 36-39 kd PDGF-immunoreactive protein 
species present in these samples were biologically active. 
In order to sUbstantiate the binding of the endothelial 
cell molecules to the PDGF cell surface receptors, competitive 
receptor binding assays were performed. Since immunoblots of 
the affinity purified endothelial cell proteins indicated the 
presence of multiple PDGF-related molecules, 1~I-Iabeled PDGF 
competition assays could not be used since this would not 
indicate which molecules in this mixture were competing for 
binding of the labeled PDGF for the receptors on the target 
cells. Because the isoforms of PDGF and the maj or PDGF 
immunorelated proteins secreted by HUVE cells are of different 
molecular weights, we were able to demonstrate receptor 
binding competition on immunoblots. Direct binding of the 
anti-PDGF immunoreactive peptides to NIH 3T3 cells was 
demonstrated by incubating monolayers of the 3T3 fibroblasts 
with the anti-PDGF affinity purified proteins (10 ngjml) for 
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2 hours at 4 C. Bound peptides were released by washing of 
the cell layer with 1 N acetic acid and quantitated by 
immunoblot analysis using anti-PDGF IgG (Fig. 8). The data 
show that the 36 kd immunoreactive peptide bound to the cell 
surface of NIH 3T3 cells. This binding could be competed by 
increasing concentrations of recombinant PDGF BB added to the 
binding media. These data suggest that the CTGF peptide binds 
to specific cell surface receptors on NIH 3T3 cell and that 
PDGF BB can compete with this binding. 
The data which we now had gave strong evidence that the 
PDGF related proteins from HUVE cells were able to bind the 
PDGF cell surface receptor of mesenchymal cells and elicit 
both chemotactic and mitogenic activity equivalent to the 
isoforms of PDGF. The biological activity was being produced 
by proteins which did not contain sequences present in the 
amino or carboxy terminals of the PDGF A or B chain peptides. 
The presence of three predominant bands on immunoblots and the 
fact that PDGF A and B chain peptides constituted 15% of the 
biologically active molecules complicated efforts to purify 








PDGF cell surface receptor binding competition 
assay with NIH 3T3 cells and HUVE affinity purified proteins 
competing with recombinant PDGF BB homodimer. 
Lane 1 contains 10 nanograms of HOVE affinity purified 
proteins and lane 9 contains 10 nanograms of recombinant 
PDGF BB homodimer. 
Lanes 2 through 8 are proteins dissociated in one well 
of a 24 well plate from the cell surface of NIH 3T3 cells with 
acetic acid. The cells in each well were incubated for 2 hours 
at 4 C with serum-free DMEM containing 10 ng of affinity 
purified proteins from HUVE cell conditioned media and 
varying concentrations of recombinant PDGF BB. The 
concentration of PDGF in lane 2 is 300 ng; lane 3 is 150 ngi 
lane 4 is 75 ng; lane 5 is 37.5 ng; lane 6 is 18.75 ng; lane 
7 is 9.4 ng and lane 8 has no addition of PDGF. 
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Cloning and saquencinq of the eDNA for connective Tissue 
Growth Factor. 
In order to further characterize these PDGF related 
molecules, we used the anti-PDGF antibody to screen an HOVE 
cell eDNA library made in the expression vector lambda gtll 
(a gift from T. Collins, Harvard). Clone selection is 
accomplished by the binding of the antibody to fusion proteins 
which are part p-galactosidase from the vector and part human 
endothelial cell protein from the HOVE eDNA inserts. Over 
500,000 recombinant clones were screened. Several clones 
which gave strong signals with the anti-PDGF antibody in the 
screening process were purified and subcloned into the M13 
phage vector and partial sequence data obtained by single 
stranded DNA sequencing. A search of the GenBank DNA 
sequence data system indicated that two of the clones picked 
contained fragments of the PDGF B chain cDNA open reading 
frame sequence. One of these clones was a 1.8 kb fragment 
similar to one previously isolated by Collins,et ale (1985) 
using a c-sis eDNA probe. This result established that the 
library screening process with the anti-PDGF antibody was an 
effective method for identifying eDNA clones producing fusion 
proteins containing PDGF related antigens. A third clone of 
500 bp was completely sequenced and no match was found in a 
homology search of all nucleotide and amino acid sequences in 
GenBank. This clone was designated DB60. In order to 
demonstrate specificity of the anti-PDGF antibody binding to 
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the fusion protein produced by clone DB60, the phage was 
plated on a 100 mm plate and the fusion protein induced by 
placing two pieces of IPTG soaked nitrocellulose on the plate 
and processed in the same manner as for the library screening. 
One filter was incubated with the anti-PDGF antibody and the 
other was incubated with the anti-PDGF antibody previously 
blocked by incubation with affinity purified HUVE cell 
secreted proteins. Antibody binding to the protein produced 
by the clone DB60 was completely blocked by the affinity 
purified proteins (Fig.9). This antibody blocking provides' 
evidence that the HUVE cell affinity purified proteins seen 
on immunoblots are the same as the endothelial cell portion 
of the fusion protein produced by clone DB60. Clone OB60 was 
subcloned into Bluescript phagemid (stratagene). A 32P-la beled 
probe was made of DB60 and used on a Northern blot of 20 ~g 
of total RNA isolated from HUVE cells (Fig. 10). The blot 
indicated probe hybridization with an mRNA of 2.4 kilobases, 
which is a message of sufficient size to produce the proteins 
in the 38 kd molecular weight range seen on immunoblots of the 
reduced affinity purified proteins. The DB60 clone was used 
to rescreen the HUVE cell cDNA lambda gt11 library and the 
largest clone isolated contained a 2100 base pair insert. A 
probe made with the 500 bp fragment in clone DB60 hybridized 
to the Eco RI insert in the new clone, labeled DB60R32, 
indicating that it was a larger eDNA clone containing 
sequences homologous to the 500 bp sequence in clone DB60 
Figure 9. 
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Figure 10. Northern blot of total cellular RNA demonstrating 
hybridization of CTGF gene probe. 
The hybridization probe for first lane was clone DB60, the 
500 bp clone selected from the gtll library. Probe for 
all other lanes was clone DB60R32,the 2100 bp eDNA of 
the CTGF gene. 
Lane 1. 2·0 J..I.g of total RNA from HUVE cells. 
Lane 2. 20 J..I.9 of total RNA from HUVE cells 
Lane 3. 20 J..I.g of total RNA from human fibroblasts. 
Lane 4. 20 ~q of total RNA from human fibroblasts 
stimulated with TGF-beta for five hours. 
Lane 5. 20 J.Lg total RNA from TGF-beta stimulated RPE 
cells. 
Lane 6. 20 ~g total RNA from human neutrophils. 
Lane 7. 20 J..I.g total RNA from human macrophages. 
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which was picked with the anti-PDGF antibody (Fig. 11). The 
2100 bp clone DB60R32 was also used as a probe in Northerns 
of total RNA from HOVE cells and hybridized with a single 2.4 
kb message (Fig. 10). Work previously done in this lab had 
shown that primary cultures of human foreskin fibroblasts 
(Soma and Grotendorst,1989) and human retinal pigment 
epithelial (RPE) cells (Campochiaro et al.,1989), upon 
stimulation with TGF-beta, secrete into culture media PDGF-
related biological acti vi ty . In both cases, the secreted 
PDGF-related proteins produce a pattern similar to the HUVE 
peptides on immunoblots using the anti-PDGF antibody with the 
major protein species in the 36-39 kd MW range. Fibroblasts 
which were not incubated with TGF-/3 did not secrete these 
peptides. Northern blots of 20 ~g of total RNA from TGF-beta 
stimulated fibroblasts (5 hours) and RPE cells (24 hours) 
using the DB60R32 clone as a probe demonstrated hybridization 
to a 2.4 kb message. Human fibroblasts which were not treated 
with TGF-/3 did not express this mRNA (Fig. 10). Pencevand 
Grotendorst (1987) had demonstrated the secretion of the 16 
kd MDGF peptide by endotoxin stimulated human macrophages and 
shown this to be the primary protein species producing the 
PDGF-related biological activity found in the conditioned 
media from these cells. In order to determine if there was 
any relationship between MDGF and CTGF or if CTGF were induced 
in leucocytes, 20 ~g of total RNA from stimulated macrophages 












Southern blot showing hybridization of Eco RI 
fragment of clone DB60 hybridizing to immobilized 2100 bp 
fragment of clone DB60R32. 
The 2100 bp Eco RI insert from the HUVE cDNA lambda gtl1 
expression library was picked by hybridization to clone 
DB60 I the clone originally picked with anti-PDGF antibody. The 
insert was subcloned into Bluescript phagemids KS and SK. 
Lanes 1 and 2 are aliquots of Bluescript KS/DB60R32 DNA uncut 
(lane 1) and cut with Eco RI (lane 2). Lanes 3 and 4 are 
aliquots of Bluescript SK/DB60R32 DNA uncut (lane 3) and cut 
(lane 4) wi th Eco RI. The DNA was run on a 1% agarose 
gel,transferred to nitrocellulose membrane and probed with the 
500 bp Eco RI insert from clone DB60. This demonstrated that 
the inserts of cDNA contained regions of homologous sequence. 
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the blots with DB60R32 indicated that the CTGF message is not 
expressed or is not expressed in abundance to be detected on 
total RNA blots as would be expected from the high 
concentrations of active peptides found in conditioned media 
(Fig. 10). 
In order to determine the size of the translation product 
of the DB6.0R32 eDNA clone, the 2100 bp insert was cloned into 
the Bluescript vector and transcribed in vitro using the T7 
polymerase promoter and the mRNA transcript was translated in 
vitro using a rabbit reticulocyte lysate method with 35S_ 
cysteine for labeling. Aliquots of the translation reaction 
were run reduced with 50 roM DTT on 12% polyacrylamide gels 
(Fig. 12). The data indicate a protein product which migrates 
at an apparent molecular weight of 38 kd and co-migrates with 
the reduced affinity purified proteins from the HUVE cell 
conditioned media. 
The 2100 bp insert of clone DB60R32 was sequenced 
initially by subcloning of Pst I and Kpn I restriction 
fragments into Bluescript and using double stranded dideoxy 
methods (Fig. 13). This determined an open reading frame of 
1076 base pairs. An Eco RI/Kpn I fragment containing the 
entire open reading frame was inserted into M13 mp18 and M13 
mp19 and both strands of the DNA were sequenced with single 
stranded dideoxy methods by primer extension using both GTP 
and the GTP analog ITP. The cDNA nucleotide sequence 
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Figure 12. In vitro translation product of eDNA clone 
DB60R32. 
Lanes 1 and 2 are an immunoblot using the anti-human PDGF 
antibody with (1) 10 ng nonreduced and (2) 100 ng reduced of 
HUVE cell affinity purified proteins from conditioned media. 
Lane 3 is an autoradiograph of 4 J.£l of a 50 J.£l rabbit 
reticulocyte in vitro translation reaction which 
incorporated 1 ~g of RNA transcript from an in vitro 
transcription reaction using the 2100 bp clone DB60R32 in 
Bluescript phagemid. Autoradiograph was exposed for 24 hours. 
CLONE ORIENTAnON AND SEQUENCING MAP FOR 
CONNECTIVE TISSUE GROWTH FACTOR cDNA1S 
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Figure 13. Sequence map of CTGF eDNA clone. 
Top line represents the 2075 bp DB60R32 clone containing 
open reading frame of CTGF. Restriction enzyme sites used in 
sUbcloning are indicated as are the ATG initiation site and 
the TGA termination codon. The position of clone 0860, picked 
from the HUVE cDNA library with anti-PDGF antibody, is 
indicated. Solid squares indicate locations of primers 
used in sequencing. Solid arrows indicate reads of single 
stranded sequencing and broken arrows indicates region in 3' 
end for which only double stranded sequencing data is 
available. 
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indicates an open reading frame of 1047 bp which encodes a 
38,000 MW protein (Fig.14). This protein has a 45% overall 
homology with the translation product of the v-src-inducible 
chicken embryo fibroblast CEF-IO mRNA (Simmons et al.,1989) 
(Fig. 15). 
CCCGGCCGACAGCCCCGAGAeGACAGCCCGGCGCGTCCCGGTCCCCACCTCCGACCACCGCCAGCGCTCCAGGCCCCGCGCTCCCCGCTCGCCGCCACC 99 
GCGCCCTCCGCTCCGCCCGCAGTGCCAACC ATG ACC Gee Gec AGT ATG GGC eee GTC CGe GTC Gee TTe GTG GTC CTC eTC 180 
Met Thr Ala Ala Ser Met Gly Pro Val Arg val Ala PIle VaL Val Leu Leu 17 
Gee CTe TGC AGe eGG CCG Gec GTC GGe CAG AAe TGC AGe GGG CCG TGC eGG TGe eeG GAe GAG COG GeG CCG eGe 255 
Ala Leu Cys Ser Arg Pro Ale Val Gly Gin Asn Cys Ser ely Pro Cya Arg Cys Pro Asp Glu Pro Ala Pro Art 42 
TGC eeG GCG GGe GTG AGe eTC GTG eTG GAC GGe TGe GGC TGe TGC CGe GTC TGC Gec AAG CAG eTG GGe GAG CTG 330 
Cys Pro Ale lily val ser L .. val Leu asp Gly Cys Gly Cys Cya Arg Val Cys Ala Lys Gin Leu Gly Glu Leu 67 
TGC Ace GAG eGe GAe eec TGC GAC eeG CAC AAG GGe eTC TTe TGT GAC TTC GGe Tec ceG Gee AAC CGe AAG ATC 405 
Cys Thr Glu Are Asp Pro era Asp Pro His Lys Sly Leu Phe Cys Asp PIle Gly Ser Pro At. AM Arg Lya He 92 
GGe GTG TGC Ace Gec AAA GAT GGT GCT cec TGC ATC TTC GGT GGT ACG GTG TAe CGe AGe GGA GAG Tee TTe CAG 480 
Gty VaL cy. Thr Ala Lya Asp eLy Ala Pro Cys lie PIle ely ely Thr Val Tyr Arg Ser ely Slu ser PIle Gln 117 
AGe AGC TGC AlG TAe CAG TGC ACG TGC CTG GAe GGG GeG GTG GGe TGC ATG ecc eTG TGC AGe ATG GAC GTT CGT 555 
Ser ser Cys L)'S Tyr Gin C)'S Thr Cys Leu Asp Gly Al. VaL GLV Cya Ret Pro Leu Cys Ser Met Asp Val Arg 149 
CTG eec AGC eeT GAC TGC eee TTC eeG AGG AGG GTC AAG CTG CCC GGG AAA TGC TGC GAG GAG TGG GTG TGT GAC 630 
Leu Pro Ser Pro Asp Cya Pro ..... Pro Arg Art! Val Lya Lal Pro Gly Lys Cya Cys Glu stu Trp Val Cya Asp 167 
GAG ecc AAG GAC eM ACe GTG GTT GGG CCT Gce CTC GeG GeT TAC eGA. CTG GAA GAC ACG TTT GGC eeA GAC teA . 705 
Gtu Pro Lys Asp Gin Tbr Val Val Gly Pro Ala Ley Ala Ala Tn Ara Leu Glu Asp Thr Phe Gl! Pro Asp Pro 192 
ACT ATG ATT AGA GCe AAC TGC CTG GTe CAG Ace lCA GAG TGG AGe Gec TGT Tee AAG Ace TGT GGG ATG GGC ATC 780 
Thr Met lie Ani Ala A!n Cys Leu VaL Gln Thr Thr GLu Trp Ser Ala Cys Ser Lys Thr Cys Gly Met Gly Ile 217 
Tce ACC CGG GTT Ace AlT GAt Ale Gee Tce TGC AGG CTA GAG AAG CAG AGC CGe eTG TGC ATG GTe AGG eey TGC 855 
ser Thr Ara Val Thr- Asn Aap AM Al. Ser Cya AF'II Leu Glu Lys Gln Ser Ara Leu Cys Met Val Arv Pro Cys Z4Z 
GAA GCT GAt CTG GAA GAG AAe ATT AAG AAG GGe AlA AAG TGC ATC CGT ACT eec AAA ATC Tee AAG eCT ATC AAG 930 
Glu Ala Asp Leu Glu slu Asn He Lys lys Sly Lys Lya Cys He AI'8 Th .. Pro Lya He Ser L,.. Pro He Lys 267 
TTT GAG CTT TeT GGe TGC ACC AGC ATG MG AtA TAC eGA GeT AAA lTC TGT GGA GTA TGT ACC GAC GGC eGA TGC 1005 
Phe Glu Leu Ser Gly Cys Thr ser Met Lys Thr lyr Are Ala Lys PIle Cys Gly val cya Thr A8p Gly Ira Cya 292 
TGC Ace CCC CAt AGA Ace ACC Ace eTG CCG GTG GAG TTC AAG TGC eCl GAt GGC GAG GTC ATG lAG AAG AAC ATG 1080 
Cys Thr Pro His Art Thr Thr Thr Leu Pro Val Glu PIle Lya Cys Pro Asp Gly Glu VaL Met LYII Lya Am Met 317 
ATG TTC ATe AAG Ace TGT Gee TCC CAT TAC MC TGT eee GGA GAC MT GAt ATt TTT GAl TCG CTG TAC TAC AGG 1155 
Met PM He lya Thr Cys Ale Cya His Tyr A8n Cys Pro Gly Asp Asn Asp Jle Phe Glu Ser L .. Tyr Tyr Art 342 
MG ATG TAC GGA GAt ATG GCA TGA. AGCCAGAGAGTGAGAGACATTAACTCATTAGACTGGAACTTGAACTGATTCACATCTCATTTTTCC 1245 











Figure 14. Nucleotide sequence and amino acid translation of 
connective Tissue Growth Factor eDNA from human vascular 
endothelial cells. 
The open reading frame for the CTGF protein extends from 
the ATG initiation site at nucleotide 130 to the TGA site at 
1177. The possible glycosylation sites at asparagines 28 and 
225 are underlined. The putative alternative splicing region 
is boxed. The 3' region contains three ATTTA sites which are 
underlined. The Genbank accession number for this CTGF eDNA 
sequence is M36965. 
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Figure 15. comparison of amino acid sequences of the 
translated eDNA for Connective Tissue Growth Factor and the 
CEF-10 mRNA translation product. 
The translated eDNA for human CTGF and avian CEF-IO have 
a 45% overall homology and a 52% homology if the putative 
alternative splicing region is deleted. This region is between 
amino acids 171 (aspartic acid) and 199 (cysteine) in the CTGF 
sequence. Homologous regions are shaded and aligned cysteine 
residues are indicated with an asterisk. 
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DISCUSSION 
The data presented here indicate that the major 
connective tissue mitoattractant secreted by HUVE cells is a 
38 kd monomeric molecule which is antigenically related to the 
dimeric platelet PDGF and competes with PDGF for binding to 
the surface of NIH 3T3 cells, but is not a product of the PDGF 
A or B chain genes. Our data indicate that HUVE cells also 
secrete both PDGF A and B chain molecules, but at much lower 
concentrations than the 38 kd monomer and these peptides 
contribute only a minor fraction of the total chemotactic and 
mitogenic activity secreted by these cells. In the biological 
assays performed with the affinity purified proteins from HUVE 
media, biological activity equivalent to 20 ng/ml of PDGF was 
obtained at low concentrations of the CTGF molecule where no 
detectable (less than 2 ng) PDGF A or B chain molecules were 
present. All biological activity could be removed by prior 
incubation of these samples with the anti-PDGF antibody. 
Because all three isomeric forms of the PDGF dimers blocked 
antibody binding to the CTGF molecule, it is evident that 
there are some common antigenic determinants shared among 
these proteins. The anti-PDGF antibody has high affinity to 
the nonreduced forms of the PDGF isomers and the CTGF molecule 
and ten-fold less affinity to the reduced forms of these 
peptides. The PDGF A and B chain monomers are not 
biologically active peptides. This suggests that there is a 
similar shape and structure between the dimeric PDGF isomers 
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and the CTGF molecule and that this conformational similarity 
results in the formation of common antigenic epitopes and the 
receptor binding sites of these molecules. 
The sequence of the eDNA for CTGF indicates an open 
reading frame of 1047 nucleotides with an initiation site at 
130 and a TGA termination site at position 1177 (Fig. 14). 
The ATG codon at position 130 and another at position 145 fit 
the concensus sequence for strong translation initiation sites 
(Kozak, 1984) and it is assumed that the first ATG is the 
predominant initiation site. There is a 40% sequence homology 
between the CTGF cDNA and the eDNA for both the A and B chains 
of PDGF and a 49% homology with the CEF-10 cDNA. If a 
putative alternative splicing region is deleted, the 
nucleotide homology to the CEF-IO mRNA increases to 59%. The 
3 1 region contains three copies of the pentanucleotide 
sequence ATTTA shown to be involved in mRNA destabilization 
and frequently found in growth factor and oncogene eDNA 3 1 
regions (Shaw and Kamen,1986). 
The CTGF open reading frame encodes a 349 amino acid 
peptide which contains 39 cysteine residues, indicating a 
protein of complex structure wi th roul tiple intramolecular 
disulfide bonds. This may explain the shift in mobility 
observed on polyacrylamide gels following reduction of the 
molecule with di thiothrei tol. The amino terminal of the 
peptide contains a hydrophobic signal sequence indicative of 
a secreted protein and there are two N-lirtked glycosylation 
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sites at asparagine residues 28 and 225 in the amino acid 
sequence. The region of the protein between residue 32 
(proline) and 208 (alanine) is the sequence of the CTGF 
peptide included in the fusion protein produced by clone DB60 
in lambda gt11 and bound the anti-PDGF antibody in the library 
screening process. There is a 45% overall sequence homology 
between the CTFG peptide and the protein encoded by the CEF-
10 mRNA transcript and the homology rises to 52% when a 
putative alternative splicing region is deleted. All 39 
cysteine residues in each peptide can be aligned with few gaps 
in the sequences. The region between amino acid residues 171 
(aspartic acid) and 199 (cysteine) in the CTGF peptide has no 
significant homology to the corresponding region in the CEF-
10 sequence (amino acids 168-224) and is 28 amino acids 
shorter. This discrepency CQuld be due to differences 
incurred during evolution of chicken and human genes. 
Significantly,this region is bordered by areas of very high 
homology (85% identity) between the two molecules and may 
indicate alternative splicing mechanisms in the expression of 
this gene. The codens for lysine at residue 170 and aspartic 
acid at residue 171 together form the AAG/G sequence 
consistent with a 3 I exon/5 I exon junction. Alternative 
splicing is found in other growth factor transcripts. The 
PDGF A chain gene exibits alternative splicing with the 
transcript produced in glioma cell line containing a highly 
basic exon of 18 amino acids that is absent in the A chain 
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transcript produced by endothelial cells (Collins et 
al.,19B?). The Vascular Endothelial Growth Factor (VEGF) is 
a 46 kd dimeric protein with mitogenic specificity for 
vascular endothelial cells and having a 20% amino acid 
homology to the PDGF A and B chain genes (Leung et al.,1989; 
Keck et al.,1989). Internal alternative splicing near the 
carboxy terminal adds 44 amino acids to the monomer (Tischer 
et a1.,1989). The biological significance of both of these 
splicing events has not yet been determined. 
Our data demonstrate that vascular endothelial cells 
grown in monolayer in vitro with 20% fetal calf serum present 
in the media constitutively secrete the CTGF peptides. The 
retinal pigment epithelial cells also constitutively secrete 
this molecule, but TGF-p stimulation increases production of 
the protein. Human dermal fibroblasts only secrete the CTGF 
peptide and express the mRNA after stimulation with TGF-p (10 
ng/ml in serum-free media). There is no PDGF-related 
biological activity in the conditioned media of cells which 
have not been stimulated with TGF-~. The fibroblasts were 
also shown to express the PDGF A chain mRNA upon TGF-13 
incubation, but immunoblots of the affinity purified proteins 
from conditioned media using the PDGF A or B chain specific 
anti-sera indicated very little production of A chain peptide 
in relation to the CTGF molecules. The fact that the affinity 
purified proteins from the conditioned media from primary 
cultures of these three cell types have similar biological 
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activity, produce the same pattern of peptides on immunoblots 
with an anti-POOF antibody and express a single 2.4 kb 
transcript on Northern blots with the clone DB60R32 as a 
probe, but only under conditions in which the proteins are 
secreted, argues strongly that the proteins are products of 
the CTGF gene. 
By using subtractive and differential screening, simmons 
et al. (1989) cloned the CEF-10 mRNA which was one of 12 
identified eDNA sequences transcribed from mRNA's that were 
induced soon after the production of the src phosphoprotein 
pp60v-src in chicken embryo fibroblasts transfected with a 
temperature sensitive vector containing a src eDNA insert. 
The CEF-10 mRNA was induced in non-transfected CEF cells when 
the serum concentration in the culture media was increased 
from 0.5% to 10%. The src protein and serum induce the 
expression of the "immediate early genes" necessary for the 
GO-G1 transition in the cell cycle (Rollins and Stiles,1989 for 
review). One major group of these genes consist of 
intranuclear DNA-binding proteins including fos, myc and jun 
which are essential for cell cycle regulation. The other 
major group of genes induced by serum and src produce 
secretory proteins with cytokine characteristics. One of 
these is the JE gene (Cochran et al.,1983) which has a cDNA 
sequence with significant homology to the cytokines Macrophage 
Colony Stimulating Factor (M-CSF) ,alpha interferon and 
interluken-2 (Rollins et al.,1988). Another is the murine KC 
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gene (Cochran et al.,19S3) which is homologous to the gro gene 
in humans (Oquendo et al.,1989; Anisowicz et al. / 19S7). The 
gro protein product is related to CEF-4, another src and serum 
inducible mRNA cloned from CEF cells (Bedard et al., 1987; 
Sugano et al. / 19B7). It is significant that other secreted 
proteins induced by src and serum in this system have cytokine 
and growth factor activities which is consistent with our 
findings for the CTGF protein. 
The PDGF molecule is the predominant identified 
competence growth factor in serum. The data presented here 
indicate that the CTGF molecule has biological activity 
similar to PDGF and binds the PDGF cell surface receptor. 
CTGF may be another competence factor which could function in 
many biological processes involving the growth of connective 
tissue. The fact that we find CTGF secreted by vascular 
endothelial cells indicates that the peptide could be present 
in serum. The conditions under which the protein would be 
secreted in vivo are not yet known. The in vitro conditions 
of endothelial cells growing in monolayer may resemble those 
during angiogenesis. 
could facilitate the 
secretion of CTGF during angiogenesis 
growth of smooth muscle cells and 
fibroblasts, thereby forming a matrix and substrate for the 
continued growth of the endothel ial cells and 
neovascularization. The secretion of CTGF by both endothelial 
cells and TGF-~ stimulated fibroblasts could be important in 
wound healing and tissue repair. Immediately after formation 
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of a wound, platelets present at the site would secrete PDGF 
and TGF-p. The PDGF would be mitogenic for the fibroblasts 
and smooth muscle cells present and set up a chemotactic 
gradient to bring more of these cells to the wound site. PDGF 
is quickly cleared from wound fluid so the CTGF peptide 
secreted by endothelial cells and TGF-/3 stimulated fibroblasts 
would continue to serve as a competence mitogen for the 
proliferation of connective tissue cells. The CTGF protein 
CQuid also playa role in atherosclerosis. PDGF mRNA has been 
detected in arterial tissues (Barrett and Benditt,1987) and 
the message appears to be elevated in atherosclerotic lesions 
(Barrett and Benditt,1988). The secretion of CTGF peptides 
by endothelial cells would stimulate the chemotaxis and growth 
of smooth muscle and fibroblasts at the plaque site, thereby 
aggrivating vessel blockage. Whether CTGF production is 
required for transformation by the src oncogene remains to be 
determined but it is interesting that CTGF could function as 
an autocrine growth factor for src transformed fibroblasts. 
Experiments to determine the transforming potential of the 
CTGF cDNA are underway. 
currently in the lab, work is underway to determine more 
information concerning the biochemistry and biological 
significance of CTGF. In order to examine genomic structure, 
fragments of the cDNA are being used as a probe to screen 
human genomic libraries. These genomic clones will enable us 
to examine the 5' end of the gene for transcription regulatory 
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sites and to examine the intron/exon structure of the gene. 
We are particularly interested in alternative splicing 
mechanisms which may be involved in the expression of this 
gene, the tissues and cell types which express alternate 
transcripts, and the differences in biological function of 
these proteins. The CTGF eDNA will also be used to probe RNA 
from various cell types and tissues to determine expression 
of the transcripts. Internal primers for peR reactions will 
be made to examine and clone possible splicing alternatives 
from eDNA of the different cell types used. The eDNA for CTGF 
will also be used to probe wound chamber RNA for expression 
of this gene during various stages of wound healing. It will 
also be interesting to probe embryonic tissue and samples from 
pathological conditions such as atherosclerotic tissue and 
solid tumors for the expression of CTGF to determine the 
involvement of this mitogen in development and disease. The 
oncogenic potential of CTGF will be investigated by 
transformation of mesenchymal cells with the CTGF eDNA in 
expression vectors. Concurrently with these experiments with 
the cDNA and gene of CTGF, we will also be examining the 
expression and secretion of the CTGF protein with antibodies 
specific to synthetic peptides representing various segments 
of the molecule. Furthermore, in order to conduct biological 
studies with pure CTGF, we will produce recombinant CTGF by 
recombinant methods in a bacterial or eucaryotic expression 
system. The goal of these investigations is a thorough 
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understanding of the CTGF protein, the gene which encodes it 
and the biological functions of CTGF in normal and 




Human umbilical vein endothelial (HOVE) cells were 
obtained from human umbilical cords by a modification of 
Jaffe (1973). Cords were obtained from local hospital 
delivery rooms and placed into a sterile cup containing 
sterile Tris buffered saline (50 mM Tris;BioRadil00 mM sodium 
chloride,FisheripH 7.4) and could be stored for up to 12 hours 
after birth at 4 C before use. Only normal, heal thy cords were 
obtained and only sections without clamp marks were used to 
collect cells to avoid smooth muscle cell contamination of 
cuI tures. Cords were removed from the container under a 
vertical flow hood and placed in a sterile tray with enough 
Modified Tyrodes Solution (MTS) (140 roM sodium chloride;3 roM 
potassium chloride, Fisher;O.3 rnM sodium phosphate 
monobasic,Fisher;5 mM dextrose,Fisher) to wet cord and wash 
off coagulated blood. A piece of sterile Tygone tubing was 
placed into one end of the vein, clamped with a plastic cable 
tie and the cable tie secured with suture to the tubing. A 
60 ml syringe was connected to the tubing by way of a valve 
and approximately 30 mls of MTS was forced through the vein 
to remove blood clots and cells. A short piece of Tygone 
tubing is then inserted into the other end of the vein and 
secured with cable tie and suture. Approximately 15 mls of 
a sterile 0.2% solution of Collagenase type IV (Worthington 
Biochemicals) in MTS was put into the vein by the syringe and 
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the other end of the vein closed off using a hemostat on the 
tubing. The cord was placed into a 37 C water bath for 20 
minutes. After incubation in the water bath, the cord was 
removed and briefly massaged with fingers to loosen cells. 
Approximately 30 mls of MTS was then forced through the vein 
with the syringe and the cells collected in a sterile 50 ml 
conical tube. The cells are pelleted by centrifugation at 
400 g for 10 minutes and resuspended in 5 mls of culture media 
( Media 199,Sigma;20% fetal calf serum, Hyclone i 50 ug/ml 
Endothelial Cell Growth Supplement, sigma (a prep. of basic 
Fibroblast Growth Factor); 90 ugjml heparin, sigma; 10 ugjml 
Gentamicin,Quality Biological). The cells were then placed 
in a 25 ml tissue culture flask (Costar) which was previously 
coated with sterile 2% gelatin solution (Sigma). The cells 
were grown at 37 C in an atmosphere of 95% air,5% CO2 • After 
reaching confluence, the cells were trypsinized (0.1% 
trypsin, Sigma; 0 .1% EDTA, sigma in phosphate buffered saline 
(PBS) (120 roM sodium chloride,2.7 roM potassium chloride in 10 
mM phosphate buffer,pH 7.4,premixed from Sigma) and passaged 
into a 75 ml culture flask. One or two more passages of the 
cells were made at a 1:3 split. Conditioned media was 
collected from the second and third passage cells. Media was 
changed every other day. Cells were identified as endothelial 
cells by their non-overlapping cobblestone morphology and by 
positive immunohistochemical staining for Factor-VIII related 
antigen (anti-Factor VIII antibody from Dako Corp.). 
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Normal Rat Kidney (NRK) fibroblasts were obtained from 
American Type Culture and NIH 3T3 cells were a gift from 
S.Aaronson (NCI,Bethesda,MD),and both cell lines were 
maintained in Dulbeco's Modified Eagles Medium 
(DMEM),(Sigma) ,10% fetal calf serum,20 ug/ml Gentamicin. 
Fetal bovine aortic smooth muscle cells were obtained from 
tissue explants (Grotendorst et al.,1981),maintained in 
DMEM,10% fetal calf serum,20 ug/ml Gentamicin and used in 
assays at second or third passage. Foreskin fibroblasts were 
grown from explants of newborn human foreskins and cultured 
in DMEM,lO% fetal calf serum,lO ug/ml Gentamicin. Cells were 
used no later then the tenth passage. 
GROWTH FACTORS AND ANTIBODIES 
Human PDGF was purified to homogeneity from platelets as 
described previously (Grotendorst, 1984). Recombinant AA, BB, 
and AB chain dimeric PDGF molecules were obtained from 
creative Biomolecules, (Hopkinton, MA). Porcine TGF-p was 
obtained from Rand D Systems, Inc. Minn. MN. FGF was obtained 
from Sigma. 
Purified PDGF or synthetic peptides 30 amino acids in 
length containing the amino and carboxy sequences of the 
mature PDGF A and B chain molecules were used to raise 
antibodies in goats. Goats were immunized with 20 J.l.g of 
purified PDGF or 50 p,g of synthetic peptide in Freunds 
complete adjuvant by multiple intradermal injections. Immune 
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sera were collected seven days after the fourth rechallange 
(in Freunds incomplete adjuvant) and subsequent rechallanges. 
The anti-PDGF antibody did not show any cross-reactivity to 
TGF-~,EGF,or FGF in immunoblot analysis. The anti-peptide 
antibodies were sequence specific and did not cross-react with 
other synthetic peptide sequences or with recombinant PDGF 
peptides which did not contain the specific antigenic 
sequence. This was determined by immunoblot and dot blot 
analysis. 
ANTIBODY AFFINITY COLUMN 
Goat anti-human PDGF IgG (150 mg) was covalently bound 
to 25 mls of Affi-Gel 10 support (BioRad) according to the 
manufacturers instructions with a final concentration of 6 mg 
IgG/ml gel. The column was incubated with agitation at 4°C 
for 18 hours with 1 liter of HUVE cell media which had been 
conditioned for 48 hours. The gel was then poured into a 
column (5 x 1.5 em), washed with four volumes of 0.1 N acetic 
acid made pH 7 ... 5 with ammonium acetate, and the antibody-bound 
PDGF immunoreactive proteins eluted with 1 N acetic acid. 
Peak fractions were determined by biological assays and 
immuunoblotting and the fractions pooled. 
CELL LABELING AND AUTORADIOGRAPHY 
Confluent cultures of HUVE cells in 75 cm2 flasks were 
labeled by incubating the cells for 22 hours in cysteine-free 
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DMEN containing 250 ~Ci/ml of ~S-cysteine (Amersham), 20% FCS 
(previously dialyzed in cysteine-free DMEM) , 40 ~g/ml 
Endothelial Cell Growth Supplement,Siqma,90 ~g/ml heparin and 
gentamicin. The ~S-labeled PDGF-immunoreactive proteins were 
affinity purified from the media with the Affi-Gel 10/anti-
PDGF column and aliquots of the proteins run on 12% 
polyacrylamide gels. As a control, an identical column was 
prepared with Affi-Gel 10 and non-immune goat IgG. The 
proteins were electroblotted to nitrocellulose and processed 
as for Western blotting using the anti-human PDGF IgG as a 
primary antibody. The nitrocellulose membranes were then 
autoradiographed on Kodak film, and the amount of 36 kD 
peptide determined using a Hoeffer densitometer and Gelscan 
software (Hoeffer Scientific). 
BIOLOGICAL ASSAYS 
Chemotactic activity was determined in the Boyden chamber 
chemotaxis assay with bovine aortic smooth muscle (BASM) cells 
or NIH 3T3 cells as previously described (Grotendorst et 
al.,1981,1987). Briefly,the chemotactic samples to be tested 
were made up in serum-free DMEM, 0.2% bovine serum albumin 
(BSA). Anti-PDGF IgG,if added to neutralize activity,was 
added at 30 ~g/ml and incubated at 4 C overnight. 
Approximately 250 ~l of test sample was put into the bottom 
chamber of a Modified Boyden Chamber and a Nuclepore filter 
(8 ~m pore size) which was previously coated with collagen 
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type I,was placed over the sample and the top chamber which 
holds the target cells was secured. The target cells were 
prepared by trypsinization for no more than two minutes to 
prevent PDGF receptor down regulation. The cells were 
suspended in DMEM,2 mg/ml BSA,pelleted by centrifugation,and 
resuspended in DMEM,O.2 mg/ml BSA at a concentration of 3 X 
105 cells per milliliter. Human fibronectin was added at a 
concentration of 5 mg/ml. Aliquots of approximately 810 ~l 
of cells was added to the top chamber and the chambers 
incubated for four hours in a humidified incubator at 37 C in 
an atmosphere of 90% air ,10% CO2 • After incubation, the 
filters were removed and the cell nuclei stained with Diff-
Quik (American Scientific Products) fixative and staining 
solutions. The top layer of cells which did not migrate into 
the pores of the filter was scraped off with a rubber 
policeman. The cells which migrated into the pores of the 
filter due to the action of the chemoattractant were either 
counted or quantitated by placing the filters into the wells 
of a 96 well plate,extracting the dye with dilute Hel,and 
reading the absorbance at 600 nanometers with an ELISA reader. 
Mitogenic assays were performed using 96 well plates and 
normal rat kidney (NRK) fibroblasts or NIH 3T3 cells as target 
cells. The cells are plated in DMEM, 10% FCS and the NRK cell 
cultures used 10-14 days after confluence and 3T3 cells 
quiesed for 2 days in serum-free DMEM, 0.2 mg/ml BSA before 
use. Sample proteins and dilutions of known standards are 
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added to the wells and the plates incubated at 37°C in 10% 
CO2 , 90% air for 18 hours, after which ~-thymidine (Amersham) 
at a final concentration of 5 ~Ci/ml was added and incubated 
for an additional 2 hours. The media was removed and the 
cells washed with cold PBS. The cells were then washed five 
times with a cold solution of trichloroacetic acid to 
precipitate the macromolecules. The macromolecules were 
removed from the wells in a solution of 0.1 N NaOH,O.l% sodium 
dodecylsulfate (5DS) (BioRad) and DNA synthesis determined 
from the 3H-thymidine incorporation into the newly formed DNA 
by scintillation counting. 
RECEPTOR COMPETITION ASSAYS 
Assays were performed using confluent cultures of NIH 3T3 
cells in 24 well plates (Costar) grown in DMEM,lO% fetal calf 
serum,lO ~g/ml Gentamicin. The growth media was removed and 
the cells washed twice with serum-free DMEM,O.2 mg/ml BSA and 
the plates placed on ice for 30 minutes in serum-free DMEM,O.2 
mg/ml BSA. Test samples and controls were made up in serum-
free DMEM,O.2 mg/ml BSA containing 5-10 ng/ml of HUVE affinity 
purified proteins and a serial dilution of one of the 
recombinant PDGF isoforms in a concentration range of 300 
ng/ml to 16 ng/ml. One milliliter aliquots of the samples 
were placed into wells of the 24 well plates and incubated on 
ice on a platform rocker for two hours. After the incubation 
period,the cells were washed three times for 10 minutes each 
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on ice with PBS. The proteins bound to the surface of the 
cells were eluted with 500 ul of 1 N acetic acid for 10 
minutes. The acetic acid elution samples were 
lyophilized,resuspended in 5 mM HCL,run on 12% polyacrylamide 
gels and immunoblotted to nitrocellulose using the anti-PDGF 
antibody. 
GEL ELBCTROPHORESIS AND IMMUNOBLOTTING 
Electrophoresis was performed on 12% polyacrylamide 
(National Diagnostics,Manville,NJ) separating gels with 4% 
stacking gels containing SOS (Laemmli,1970) unless otherwise 
stated. The gels were run on mini-gel apparatus ("Mighty-
Small" Hoeffer Scientific). Immunoblotting was performed by 
electroblotting the proteins to a nitrocellulose membrane 
(Schleicher and Schuell,45 um pore size). Electroblotting was 
done using the "Multiphor II" blotting apparatus (BRL) in a 
buffer of 0.025 M Tris,O.192 M glycine,20% methanol,pH 8.3. 
The membrane was incubated in 50 roM Tris-HCl, pH 7.4, 100 mM 
NaCl (TBS) with 5% non-fat dry milk (Carnation) at 25°C for 
1 hour to block non-specific antibody binding. The blocking 
solution was removed and the antibody (15 ~g/ml) added in TBS 
containing 0.5 % non-fat dry milk and 1 ~gjml sodium azide and 
incubated overnight at 2S Q C. The membranes were then washed 
5 times in TBS, 0.5% milk for 10 minutes each wash and then 
incubated with alkaline phosphatase conjugated affinity 
purified rabbit anti-goat IgG (Organon TeknikajCappel, 
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Malvern,PA) at a 1:1000 dilution in TBS containing 0.5% milk 
at 25°C for 1 hour. The filters were then washed with TBS 
five times, 10 minutes each time, and the blot developed using 
an alkaline phosphatase substrate solution (0.1 M Tris-Hel, 
pH 9, 0.25 mg/ml nitro blue tetrazolium,Sigma; 0.5 mg/ml 5-
bromo-4-chloro-3-indolyl phosphate,Sigma). 
RNA ISOLATION AND NORTHERN BLOTTING 
Total RNA was isolated from tissue culture cells by the 
method of Chomczynski and Sacchi (1987). Cells in monolayer 
were lysed in the culture flask in a solution of 4 M 
guanidinium thiocyanate,Boehringer Mannhiem;25 mM sodium 
citrate,pH 7.0,Sigma;O.5% sarcosyl,sigmaiO.l M 2-
mercaptoethanol, BioRad. To the lysed cells solution,1/10 vol. 
of 2 M sodium acetate,pH 4,equal vol. phenol,1/5 vol. of 
chloroform/isoamyl alcohol were added sequentially with 
mixing. The solution was centrifuged at 10,000 9 for 20 
minutes at 4 C and the RNA in the aqueous phase was 
precipitated with an equal volume of isopropanol at -20 C for 
1 hour. The RNA was pelleted by centrifugation and the pellet 
resuspended in the above guanidinium thiocyanate solution and 
again precipitated with isopropanol. 
Lyophilized RNA was resuspended in gel loading buffer of 
50% formamide,lX MOPS (20 roM MOPS Boehringer Mannheim,5 roM 
sodium acetate, 1 roM EDTA, pH 8 . 0) , 6 .7% formaldehyde, 6% 
glycerol,bromophenol blue and heated at 95 C for two minutes 
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before loading (20 ~g per lane total RNA) onto 2.2 M 
formaldehyde,1% agarose gels and run at 50 volts. Integrity 
of RNA was determined by ethidium bromide staining and 
visualization of 18S and 28S rRNA bands. After the run, gel 
was soaked in 10 X sse (lX,O.15 M NaCl,0.015 M sodium citrate) 
for 40 min. total with one solution change. RNA was 
transfered to nitrocellulose by blotting overnight with 10 X 
sse. The nitrocellulose was air dried and baked at 80 C for 
2 hours in a vacuum oven. The membrane was prehybridized for 
30 min. at 46 C in a solution of 50% deionized formamide,0.9 
M NaCl,50 mM sodium phosphate pH 7.0,5 mM EDTA,2X Denhardts 
solution,O.l% 8D8,75 ~g/ml tRNA,100 ~g/ml depurinated salmon 
sperm DNA,5 ~g/ml poly-A RNA (all Sigma). Hybridization is 
overnight at 46 C in the same solution with the addition of 
5 X 105 CPM per ml of 32P-la beled probe. Normally for Northern 
blots the entire plasmid was labeled and used as a probe. 
Labeling was done with a random prime labeling kit from 
Boheringer Mannheim according to instructions provided. After 
hybridization,membranes were washed twice in 2X SSC,O.l% SDS 
for 15 minutes each at room temperature, once for 15 minutes 
in O.IX SSC,O.l% 5DS,room temp. and a final 15 minute wash in 
O.lX SSC,O.I% SOS at 46 C. Blots were autoradiographed at 
-70 C on Kodak X-omat film. 
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DNA CLONING, SEQUENCING AND LIBRARY SCREENING 
Standard molecular biology techniques were used to 
subclone and purify the various DNA clones (Sambrook et al., 
1989). Clone DB60 was picked from a lambda-gtll HOVE cell 
cDNA library by induction of the fusion proteins and screening 
with anti-PDGF antibody. Approximately 2 x 105 phage were 
incubated with 600 JLI of an overnight culture of YI090 
bacteria at 37 C for 20 minutes. The phage infected bacteria 
were plated in 0.6% top agarose (Boehringer Mannheim) onto 
1.5% bottom agarose (LB medium) plates (150 rom diameter, 
Fisher) and placed in a 42 C incubator until plaques were 
visible (approx. 6 hrs). Nitrocellulose circles (45 ~m pore 
size,Schleicher and Schuell) previously soaked in 10 roM IPTG 
(5 1 -3',Inc.) and dried were placed on top of the plaques on 
the agarose plates and the plates incubated at 37 C for 2 
hours. This process induced production of the beta-
galactosidase/human cDNA fusion protein by the phage. The 
nitrocellulose membranes were then removed from the plates, the 
plates placed at 4 e,and the membranes placed in a blocking 
solution of Tris-buffered saline (TBS) (50 roM Tris,lOO mM 
NaCl,pH 7.4) and 5% nonfat dry milk and incubated with 
agitation at room temperature for 1 hour. The blocking 
solution was removed and anti-PDGF IgG (previously incubated 
overnight with a Y1090 cell lysate in TBS to prevent 
nonspecific antibody binding to bacterial proteins) at a 
concentration of 3 ~g/ml in TBS with 0.5% nonfat dry milk was 
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added in sufficient volume to cover the membranes was added 
and the containers placed on a rocker at 4 C for at least 12 
hours. The membranes were washed with TBS,O.5% milk five 
times for 15 min. each time. The secondary antibody,rabbit 
anti goat IgG,alkaline phosphatase conjugated at a 
concentration of 1 J,Lg/ml in TBS, o. 5% milk was added and 
incubated at 4 C for 1 hour with agitation. The membranes 
were again washed with TBS,O.5% milk five times for 15 min. 
each. Alkaline phosphatase substrate solution (0.1 M Tris,pH 
9.0,0.25 mg/ml nitro blue tetrazoleum,O.5 mg/ml 5-bromo-4-
chloro-3-indolyl phosphate) was added and incubated at room 
temp. The solution was changed several times and a fresh 
solution usually left on overnight. The membranes were dried 
and positive clones (as indicated by circles of precipitate 
from the alkaline phosphatase substrate solution) picked by 
matching the membranes with the plaques on the agarose plates. 
Plaques picked were rescreened and positive clones replated 
at low titer and isolated. 
The EcoR I insert from clone DB60 was cloned into the M13 
phage vector and single stranded DNA obtained for clones with 
the insert in opposite orientations. These M13 clones were 
then sequenced by the dideoxy method (Sanger, 1977) using the 
Sequenase kit (U. S. Biochemical) and ~S-dATP. Both strands 
of DNA for this clone were completely sequenced using primer 
extension and both GTP and ITP chemistry. The sequencing 
reactions were done according to the manufacturors 
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instructions. Aliquots of the sequencing reactions were run 
on both 6% acrylamide (16 hours) and 8% acrylamide (6 hours) 
gels,vacuum dried and autoradiographed for at least 18 hours. 
The eDNA fragment from clone DB60 was ~P-CTP labeled and 
used to rescreen the HUVE cell eDNA lambda gt11 library. 
Approximately 100,000 recombinants were plated and rescreened 
by standard methods (Sambrook et al., 1989) • The 2100 bp 
clone designated DB60R32 was subcloned into Bluescript 
phagemid. Subclones were made of Pst I,Kpn I,and Eco RI/Kpn 
I restriction fragments also in Bluescript. These subclones 
were sequenced by double stranded plasmid DNA sequencing 
techniques using Sequenase as described above. The 1458 bp 
Eco RljKpn I clone containing the open reading frame was 
subcloned into M13 mp18 and M13 mp19 and both strands of DNA 
were completely sequenced using single stranded DNA sequencing 
techniques with primer extension and both GTP and ITP 
chemistry. 
IN VITRO TRANSCRIPTION AND TRANSLATION ASSAYS 
In vitro transcription reactions were done using the 2100 
bp cDNA clone DB60R32 in the Bluescript KS vector. The 
plasmid was cut with Xho I which cuts the plasmid once in the 
multiple cloning site of the vector 3' to the eDNA insert. 
The T7 promoter site located 5' to the eDNA insert was used 
for transcription. The in vitro transcription,s were done with 
a kit supplied with the Bluescript vector by stratagene and 
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the manufacturors instructions were followed. The reactions 
were done in a final volume of 25 ~1 in a buffer of 40 mM 
Tris, pH 8. 0 . 8 mM MgC12 , 2 roM spermidine and 50 mM NaCl. In 
addition,the reactions contained 500 uM rATP,rUTP,rCTPi5 ~M 
rGTPi500 ~M 7meGpppG cap;30 ~M DTT;l ~g Proteinase K treated 
DB60R32,in Bluescript;l U RNase inhibitor and 10 U of T7 
polymerase. The reactions were incubated for 1 hour at 37 C. 
The reaction mix was treated with RNase-free DNase for 15 min. 
at 37 C, phenol:chloroform extracted and the RNA precipitated 
with ethanol. 
In vitro translation reactions were done using nuclease 
treated rabbit reticulocyte lysate and ~S-cysteine in a 
cysteine-free amino acid mix for labeling of the peptide. The 
reactions were done with a kit supplied from Promega and the 
manufacturors instructions were followed. The reactions were 
done in a 'final volume of 50 ILl and included 35 J.l.l of the 
supplied rabbit reticulocyte lysate,20 JLM amino acid mix 
(minus cysteine) 14 U RNase inhibitor, 35s - cysteine 1 mCijml (1200 
Ci/mMole, DuPont) , and serial dilutions of mRNA from the in 
vitro transcription reactions in concentrations ranging from 
100 to 1000 nanograms per reaction tube. The mRNA samples 
were heat treated at 67 C for 10 minutes and cooled on ice 
immediately before use. The reactions were incubated at 30 
C for 60 minutes. Aliquots of the reactions were run reduced 




Abraham,J.A.,J.L. Whang,A. Tumulo,J. Friedman, K.A. 
Hjerrild,D. Gospodarowicz and J .C. Fiddes (1986). "Human basic 
fibroblast growth factor: Nucleotide sequence and genomic 
organization. II EMBO J. 5,2523-2528. 
Anisowicz,A.,L. Bardwell and R. Sager (1987). "Constitutive 
overexpression of a growth-regulated gene in transformed 
Chinese hamster and human cells. II Prac. Natl. Acad. Sci. USA 
84,7188-7192. 
Antoniades,H.N.,C.D. Scher and C.D. Stiles, (1979). 
"Purification of platelet-derived growth factor." Proc. Natl. 
Acad. Sci. USA 76,1809-1813. 
Antoniades, H.N. (1981). "Human platelet derived growth factor 
(PDGF):purification of PDGF I and PDGF II and separation of 
their reduced sUbunits." Prac. Natl. Acad. Sci.USA 78,7314-
7317. 
Armelin,H.A.(1973). "Pituitary extracts and steroid hormones 
in the control of 3T3 cell growth." Prac. Natl. Acad. Sci. 
USA. 70,2702-2706. 
Assoian,R.K. ,A. Komoriya,C.A. Meyers,D.M. Miller and M.B. 
Sporn (1983). "Transforming growth factor beta in human 
platelets: Iqentification of a major storage site,purification 
and characterization." J. BioI. Chern. 258,7155-7160 
Baird,A. and T. Durkin (1986). "Inhibition of endothelial cell 
proliferation by type-beta transforming growth factor: 
interactions with acidic and basic fibroblast growth factors. II 
Biochem. Biophys. Res. Cerom., 138,476-482. 
Barrett,T.B.and E.P. Benditt (1987). "sis (platelet-derived 
growth factor B chain) gene transcript levels are elevated in 
human atherosclerotic lesions compared to normal artery." 
Proe. Natl. Acad Sci USA 84,1099-1103. 
Barrett,T.B. and E.P. Benditt (1988). "Platelet-derived 
growth factor gene expression in human atherosclerotic plaques 
and normal artery wall. II Proc. Natl. Acad Sci. 85,2810-2814. 
Bedard,P-A. ,D. Alcorta,D.L. Simmons,K-C. Luk and R.L. Erickson 
(1987) . "Constitutive expression of a gene encoding a 
polypeptide homologous to biologically active human platelet 
protein in Rous sarcoma virus-transformed fibroblasts." Proe. 
Natl. Acad. Sci. USA 84,6715-6719. 
82 
Betsholtz,C. ,B. Westermark,B. Ek and C.H. Heldin. (1984). "Co-
expression of PDGF-like growth factor and PDGF receptors in 
human osteosarcoma cell line: implications for autocrine 
receptor activation." Cell 39,447-457. 
Bonthron, D.T.,C.C. Morton,S.H. Orkin, and T. Collins (1988). 
"Platelet-derived growth factor A chain: Gene structure, 
chromosomal location, and basis for alternative mRNA splicing. 
Pree. Natl. Acad. Sci. USA 85,1492-1496. 
Bowen-Pope,D.F. and R. Ross (1983). "Is epidermal growth 
factor present in human blood? Interference with the 
radioreceptor assay for epidermal growth factor." Biochem. 
Biophys. Res. 114,1036-1041. 
Bowen-Pope,D.F.,C.E. Hart and R.A. Seifert (1989). "Sera and 
conditioned media contain different isoforms of platelet-
derived growth factor (PDGF) which bind to different classes 
of PDGF receptor." J. BioI. Chern. 264,2502-2508. 
Campochiaro,P.A.,R. sugg,G.R. Grotendorst and L.M. Hjelmeland 
(1989). "Retinal pigment epithelial cells produce PDGF-like 
proteins and secrete them into their media. II Exp. Eye Res. 
49,217-227. 
Cheifetz,S.,J.A. Weatherbee,M.L-S. Tsang,J.K. Anderson,J.E. 
Mole,R. Lucas and J. Massague (1987). "The transforming 
growth factor-beta system, a complex pattern of cross-reactive 
ligands and receptors." Cell 48,409-415. 
Cochran,B.H.,A.C. Reffel and C.D. Stiles (1983). "Molecular 
cloning of the gene sequences regulated by platelet-derived 
growth factor." Cell 33,939-947. 
Cohen,S. (1962). "Isolation of a mouse submaxillary gland 
protein accelerating incisor eruption and eyelid opening in 
the new-born animal." J. BioI. Chern. 237,1555-1562. 
Cohen,S. and G. carpenter (1975). "Human epidermal growth 
factor: isolation and chemical and biological properties. II 
Proc. Natl. Acad. sci. USA 72,1317-1321. 
Collins, T.,D. Ginsburg,J.M. Boss,S.H. Orkin and J.S. Fober 
(1985). "Cultured human endothelial cells express platelet-
derived growth factor B chain: eDNA cloning and structural 
analysis." Nature 316,748-750. 
Collins, T.,D.T. Bonthron,and S.H. Orkin (1987). "Alternative 
splicing affects function of encoded platelet-derived growth 
factor A chain." Nature 328,621-624. 
Dalla Favera,E.P. Gelmann,R.L. Gallo and F. Wong-Staal (1981). 
83 
itA human one gene homologous to the transforming gene (v-sis) 
of simian sarcoma virus." Nature 292,31-35. 
Delli-Bovi,p.,A.M. Curatola,F.G. Kern,A. Greco,M. Ittman and 
c. Basilica. (1987). "An oncogene isolated by transfection of 
Karposi's sarcoma DNA encodes a growth factor that is a member 
of the FGF family." Cell 50,729-737. 
Delli-Bovi, P. ,A.M. Curatola, K.M. Newman, Y. Sato, D. Moscatelli, 
R.M. Hewick,D.B. Rifkin and C. Bascilico. (1988). 
"Processing, secretion and biological properties of a novel 
growth factor of the fibroblast growth factor family with 
oncogenic potential." Mol. Cell BioI. 8,2933-2941. 
Derynck,R.,J.A. Jarrett,E.Y. Chen,D.H. Eaton,J.R. Bell,R.K. 
Assoian,A.B. Roberts,M.B. Sporn and D.V. Goeddel (1985). 
"Human transforming growth factor betacDNA sequence and 
expression in tumor cell lines." Nature 316,701-705 .. 
DiCorleto, P.E. (1984). "Cultured endothelial cells produce 
multiple growth factors for connective tissue cells." Exp. 
Cell Res. 153,167-172. 
Dickson,C. and G. Peters. (1987). "Potential oncogene product 
related to growth factors." Nature 326,833. 
Doolittle,R.F. ,M.W. Hunkapiller,L.E. Hood,S.G. Devare,K.C. 
Robbins,S.A. Aaronson and Gimbrone, M.A., A. Hammacher, c. 
Betsholtz,B. Westermark and C-H. Heldin (1987). "Cultured 
human endothelial cells express platelet-derived growth factor 
A chain. II - Am. J. Physio!. 126,7-12. 
Doolittle,R.F.,M.W.Hunkapiller,L.E. Hood,S.G. Devare,K.C. 
Robbins,S. A. Aaronson and H.N. Antoniades (1983). "Simian 
sarcoma virus one gene v-sis is derived from the gene (or 
genes) encoding a platelet-derived growth factor." Science 
221,275-277. 
Downward,J.,Y. Yarden,E. Mayes,G. Scarce,N. Totty,P. 
Stockwell,A. Ullrich,J. Schlessinger and M.D. Waterfield 
(1984). "Close similarity of epidermal growth factor receptor 
and v-erb-B oncogene protein sequences. II Nature 307,521-527. 
Esch,F.,A. Baird,N. Ling,N. Ueno,F. Hill,L. Denoroy,R. 
Klepper,D. Gospodarowicz,p. Bohlen, and R. Guillemin. (1985). 
"Primary structure of bovine pituitary basic fibroblast growth 
factor (FGF) and comparison with the amino terminal sequence 
of bovine brain acidic FGF." Proe. Natl. Acad. Sci. USA 
82,6507-6511. 
Frater-Schroder,M.,G. Muller,W. Birchmeier P. Bolen. (1986). 
"Transforming growth factor-beta inhibits endothelial cell 
84 
proliferation. II Biochem. Biophys Res. Camm. 137,295-302. 
Frolick,C.A.,L.L. Dart,C.A. Dryeras,D.M. smith and M.B. Sporn 
(1983). "Purification and initial characterization of type B 
transforming growth factor from human placenta. II Proc. Natl. 
Acad. Sci. USA 80,3676-3680. 
Gospodarowicz,D. (1974). "Localization of a fibroblast growth 
factor and its effect alone and with hydrocortizone on 3T3 
cell growth." Nature 249,123-127. 
Greenburg,M.E.and E.B. Ziff (1984). "stimulation of 3T3 cells 
induces transcription of the c-fos proto-oncogene." Nature 
311,433-438. 
Gregory,H. (1975). "Isolation and structure of urogastrone 
and its relationship to epidermal growth factor. II Nature 
257,325-327. 
Gronwald, R. G. K. , F. J. Grant, B. Haldeman, c. E. Hart, POI Hara, F. s. 
Hagen,R.Ross,D.F. Bowen-Pope,and M. Murry. (1988). "Cloning 
and expression of a cDNA coding for the human platelet-derived 
growth factor receptor: evidence for more than one receptor 
class" Prec. Natl. Acad. Sci. USA 85,3435-3439. 
Grotendorst, G.R. and G.R. Martin (1986). "Cell movements in 
wound-healing and fibrosis." Rheumatology 10,385-403. 
Grotendor~t, G.R., H. E. Seppa,H. K. Kleinman, and G. R. Martin 
(1981). "Attachment of smooth muscle cells to collagen and 
their migration toward platelet derived growth factor." Proe. 
Natl. Acad. Sci. USA 78,3669-3672. 
Grotendorst, G.R. (1987) "Spectrophotometric assay for the 
quantitation of cell migration in the Boyden chamber 
chemotaxis assay." Methods in Enzymol. 147,144-152. 
Grotendorst, G. R. (1984). "AI teration of the chemotactic 
response of NIH/3T3 cells to PDGF growth factors, 
transformation and tumor promoters." Cell 36,279-285. 
Hart,e.H.,J.W. Forestrom,J.D. Kelly,R.A. Smith,R. Ross,M.J. 
MurraY,and D.F. Bowen-Pope (1988). "Two classes of PDGF 
receptor recognize different isoforms of PDGF. " 
Science,240,1529-1531. 
Heimark,R.L. ,D.R. Twardzik and S.M. Schwartz (1986). 
"Inhibition of endothelial cell regeneration by type-beta 
transforming growth factor from platelets. It Science 233,1078-
1080. 
Heldin,C.H.,B. Westermark and A. wasteson (1979) • 
85 
"Purification of platelet-derived growth factor and partial 
characterization. II Prec. Natl. Acad. sci. USA 76,3722-3726. 
Heldin,C.H.,B. Westermark and A. Wasteson (1981). "Specific 
receptors for platelet-derived growth factor on cells derived 
from connective tissue and qlia." Pree. Natl. Acad. Sci. USA 
78,3364-3368. 
Heldin,C.H.,A. Johnson,S. Wennergren,C. wennergren,C. 
Wernstedt,C. Bet'sholtz and B. Westermark (1986). "A human 
osteosarcoma cell line secretes a growth factor structurally 
related to a homodimer of PDGF A chains. II Nature 319,511-514. 
Heldin,C-H,G. Backstrom,A. Ostman,A. Hammacher,L. Ronstrand,K. 
Rubin,and B. Westermark (1988). "Binding of different dimeric 
forms of PDGF to human fibroblasts: evidence for two separate 
receptor types." EMBO J. 7,1387-1393. 
Jaffe,E.A.,R.L. Nachman,C.G. Becker and C.R. Minick (1973). 
"Culture of human endothelial cells derived from umbilical 
veins." J. Clin. Invest. 52,2745-56. 
Jaye,M.,R. Howk,W. Burgess,G.A. Ricca,I-M. Chiu,M.W. 
Ravera,S.J. Q'Brian,W.S. Modi,T. Maciag and W.N. Drohan 
(1986). "Human endothelial cell growth factor: 
cloning, nucleotide sequence and chromosome localization." 
Science 233,541-544. 
Kartha, S • ,.,D. M. Bradham, G • R. Grotendorst and G. Toback (1988). 
"Kidney epithelial cells express the c-sis prot-oncogene and 
secrete PDGF-like proteins: evidence for a paracrine 
mechanism." Amer. J. Physiol. 255,F800-F806. 
Keck,P.J. ,S.D. Hauser,G. Krivi,K. Sanzo,T. Warren,J. Edeer and 
D.T. Connolly (1989). "Vascular Permeability Factor, an 
endothelial cell mitogen related to PDGF." Science 246,1309-
1312. 
Kelly,K.,B.H. Cochran,C.D. stiles and P. Leder (1983). IICel1 
specific regulation of the c-myc gene by lymphocyte mitogens 
and platelet-derived growth factor." Cell 33,939-947. 
Kohler, N., and A. Lipton (1974). "Platelets as a source of 
fibroblast growth-promoting activity." EXp. Cell. Res. 
87,297-301. 
Kozak,M. (1984). "Point mutations close to the AUG initiator 
codon affect the efficiency of translation of rat 
preproinsulin in vivo." Nature 308,241-246. 
Laemmli,U.K. (1970). "Cleavage of structural proteins during 
assembly of the head of bacteriophage T4." Nature (Land.) 
86 
227,680-685. 
Leof,E.B.,W. Wharton,J.J. Van Wyk,and W.J. Pledger (1982). 
"Epidermal growth factor and somatomedin C regulate G1 
progression in competent BALBjc 3TJ cells." EXp. Cell Res. 
141,107-111. 
Leof,E.B.,J.J. Van Wyk,E.J. O'Keefe and W.J. Pledger (1983). 
"Epidermal growth factor is required only during traverse of 
early G1 in PDGF stimulated density-arrested BALBjc 3T3 
cells." EXp. Cell Res. 147,202-205. 
Leof IE. B. ,J .A. Proper ,A. S. GOllstin,G. D. Shipley, P.E. DiCorleto 
and H.L. Moses (1986). "Induction of c-sis mRNA and activity 
similar to PDGF by TGF-beta:A proposed model for indirect 
mitogenesis involving autocrine activity. I' Proe. Natl. Acad. 
Sci. USA 83,2453-2457. 
Leung, D. W • , G. Cachianes, W-J. Kuang, D", V '" Goeddel and N. Ferrara 
(1989). "Vascular Endothelial Growth Factor is a secreted 
angiogenic mitogen. II Science 246,1306-1309. 
Maciag,T.,T. Mehlman,R. Friesel,and QA. B. Schreiber (1984). 
"Heparin binds endothelial cell growth factor,the principle 
endothelial cell mitogen in bovine brain." Science. 255,932-
935. 
Marquardt,H.,M.W. Hunkapiller,L.E. Hood and G.J. Todaro 
(1984). "Rat transforming growth factor type 1:structure and 
relation to epidermal growth factor. II Science 223,1073-1082. 
Martinet, Y., P. B. Bitterman,J.F. Marnex,G.R.Grotendorst, 
G.R. Martin, and R.G. Crystal (1986) • "Activated human 
monocytes express the c-sis prot-oncogene and release a 
mediator showing PDGF-like activity." Nature 319,158-160. 
Massague,J. (1983). "Epidermal growth factor-like 
transforming growth factor II . Interaction with epidermal 
growth factor receptors in human placenta membranes and A431 
cells. II J. BioI. Chern. 258,13614-13620. 
Massague,J. (1984). "Type B transforming growth factor from 
feline sarcoma virus transformed rat cells-isolation and 
biological properties." J. BioI. Chern. 259,9756-9761. 
Masui,T.,L.M. Wakefield,J.F. Lechner,M.A. LaVeck,M.B. Sporn 
and C.C. Harris, (1986). "Type B transforming growth factor 
is the primary differentiation-inducing serum factor for 
normal and human bronchial epithelial cells." Proc. Natl. 
Acad. Sci. USA 83,2438-2442. 
Muller,G.,J. Behrens,U. Nussbaumer,P. Bohlen and W. Birchmeier 
87 
(1987). "Inhibitory action of transforming growth factor beta 
on endothelial cells." Proc. Natl. Acad. Sci. USA 84,5600-
5604. 
Oka,Y. and D.N. Orth (1983). IIHuman plasma epidermal growth 
factor/beta-urogastrone is associated with blood platelets." 
J. Clin. Invest. 72,249-259. 
Oquendo,P.,J. Alberta,D. Wen,J.L. Greycar,R. Derynck and C.D. 
stiles (1989). liThe platelet-derived growth factor-inducible 
KC gene encodes a secretory protein related to platelet Q-
granule proteins." J. BioI. Chem. 264,4133-4137. 
Owen,A.J. ,P. Pantazis,and H.N. Antoniades (1984). "Simian 
sarcoma virus-transformed cells secrete a mitogen identical 
to platelet-derived growth factor." Science 225,54-56. 
Pardee,A.B. (1989). "G1 events and regulation of cell 
proliferation. II Science 246,603-608. 
Pencev, D. and G.R. Grotendorst (1988). "Human peripheral 
blood monocytes secrete a unique form of PDGF." Oncogene Res. 
3,333-342. 
Robbins, K.C., H. N. Antoniades,S.G. Devare,M.W. Hunkapiller, 
S.A. Aaronson, (1983). "structural and immunological 
similarities between simian sarcoma virus gene product(s) and 
human platelet-derived growth factor." Nature 305,605-608. 
Roberts,A.B.,M.A. Anzano,L.C. Lamb,J.M. Smith and M.B. Sporn 
(1981). "New class of transforming growth factors potentiated 
by epidermal growth factor:isolation from non-neoplastic 
tissues." Proc. Natl. Acad. sci. USA 78,5339-5343. 
Raberts,A.B. ,M.A. Anzano,L.M. Wakefield,N.S. Roche,D.F. stern 
and M.B. Sporn (1985). "Type B transforming growth factor:a 
bifunctional regulator of cellular growth. II Proc. Natl. Acad. 
Sci. USA 82,119-123. 
Rollins,B. J.,E.D. Morrison and C.D. stiles (1988). "Cloning 
and expression of JE, a gene inducible by platelet-derived 
growth factor and whose product has cytokine-like properties." 
Prac. Natl. Acad. Sci. USA 85,3738-3742. 
Rollins,B.J. and C.D. stiles (1989). IISerum-inducible genes. II 
Adv. Cancer Res. 53,1-32. 
Ross, R., J. Glomset,B. Kariya,and L. Harker (1974). "A 
platelet dependent serum factor that stimulates the 
proliferation of arterial smooth muscle cells in vitro. II 
Pree. Natl. Acad. Sci. USA 71,1207-1210. 
88 
Sambrook,J.,E.F. Fritsch and T. Maniatis (1989). Molecular 
cloninq.a laboratory manual. Second edition. Cold Spring 
Harbor Laboratory Press. Cold Spring Harbor,N.Y. 
Sanger,F.,S. Miklen,and A.R. Coulson (1977). ilONA sequencing 
with chain-terminating inhibitors. II Prac. Natl. Acad Sci. 
84,5463-5467. 
Shaw,G. and R. Kamen (1986). itA conserved AU sequence from 
the 3' untranslated region of GM-CSF mRNA mediates selective 
mRNA degradtion." Cell 46,659-667. 
Shers, C.J . , c. w. Rollenmier, R. Sacca, M. F. Roussel, A. T. Look, and 
E.R. Stanley (1985). "The c-fms protooncogene product is 
related to the receptor for the mononuclear phagocyte growth 
factor CSF-l." Cell 41,665-676. 
Shimokado, K., E.W. Raines,D.K. Madtes,T.B. Barrett,E.P. 
Benditt and R. Ross (1985). "A significant part of 
macrophage-derived growth factor consists of at least two 
forms of PDGF." Cell 43,277-286. 
Shipley,G.D.,R.F. Tucker,H.L. Moses (1985). "Type B 
transforming growth factor/growth inhibitor stimulates entry 
of monolayer cultures of AKR-2B cells into S phase after a 
prolonged prereplieative interval." Prac. Natl. Acad. Sci. 
82,4147-4151 
Simmons,D."L. iB.L. LevYiY. Yannoni and R.L. Erikson (1989). 
"Identification of a phorbol ester-repressible v-src-inducible 
gene. II Pree.Natl. Acad. Sci USA 86,1178-1182. 
Sitaras, N.M., E. Sariban,P. pantazis,B. Zetter and H.N. 
Antoniades (1987) . "Human iliac artery endothelial cells 
express both gene encoding the chains of platelet-derived 
growth factor (PDGF) and synthesize PDGF-like mitogen." J. 
Cell. Physiol. 132,376-380. 
Soma,Y. and G. Grotendorst (1989). "TGF-B stimulates primary 
human skin fibroblast DNA synthesis via an autocrine 
production of PDGF-related peptides. II J • Cell. Physiol. 
140,246-253. 
stiles,C.D.,G.T. Capone,C.D. Scher,H.N. Antoniades,J.J. Van 
Wyk and W.J. Pledger (1979). "Dual control of cell growth by 
somatomedins and platelet-derived growth factor." Proc. Natl. 
Acad. Sci. USA 76,1279-1283. 
stroobant,PI and M.D. Waterfield (1984). "Purification and 
properties of porcine platelet-derived growth factor." EMBO 
J. 3,2963-2967. 
89 
Sugano,S.,M.Y. Stoeckle and H. Hanafusa (1987). 
"Transforamtion by Rous sarcoma virus induces a novel gene 
with homology to a mitogenic platelet protein. II Cell 49,321-
328. 
Takahara,K.,E. C. Leroy,G.R. Grotendorst (1987). "TGF-B 
inhibition of endothelial cell proliferation:Alteration of EGF 
binding and EGF induced growth regulatory (competence) gene 
expression." Cell 49,415-422. 
Taylor,J.M. ,W.M. Mitchell and S. Cohen (1972). 




ten Dijke,P.,P. Hansen,K.K. Iwata,C. Peeler and J.G. Foulkes 
(1988). "Identification of a new member of the transforming 
growth factor type f3 gene family." Proe. Natl. Acad. Sci. USA 
85,4715-4719. 
Thomas,K.A.,M. Rios-Candelore,and S. Fitzpatrick (1984). 
"Purification and characterization of acidic fibroblast growth 
factor from bovine brain." Prac. Natl. Acad. Sci. USA 81,357-
361. 
Tischer,E.,D. Gospodarowicz,R. Mitchell,M. Silva,J. 
Schilling,K. Lau,T. Crisp,J.C. Fiddes and J.A. Abraham (1989). 
"Vascular Endothelial Growth Factor: a new member of the 
platelet-derived growth factor gene family." Biochem. 
Biophys. Res. Camm. 165,1198-1206. 
Tong, B.D., D.E. Auer,M. Jaye,J.M. Daplow,G. Ricca,E. 
McConathy, W.,Drohan ,and T.F. Neuel (1987). "eDNA clones 
reveal differences between human glial and endothelial cell 
platelet-derived growth factor A-chains." Nature, 328,619-
621. 
Towbin, H., T. Staehelin and J. Gorden (1979). 
"Electrophoretic transfer of protein from polyacrylamide gels 
to nitrocellulose sheets: procedure and some application." 
Prac. Natl. Acad. Sci. USA 76,4353-4356. 
Tucker,R.F.,G.S. Shipley,H.L. Moses,R.W. Holley (1984). 
"Growth inhibitor from BSC-l cells closely related to platelet 
type beta transforming growth factor." Science 226,705-707. 
waterfield,M. , D. ,G. T. Scrace,N. Whittle, P. Stroobant,A. 
Johnsson,A. Westermark,C-H Heldin,J. Huang and T. Deuel. 
(1983). "Platelet-Derived growth factor is structurally 
related to the putative transforming proteins p28 sis of 
simian sarcoma virus. II Nature 304,35-39. 
Wenger,R.H.,A.N. Wicki,A. Walz,N. Keiffer and K.J. Clemetson 
90 
(1989). "Cloning of eDNA coding for connective tissue 
activating peptide III from a human platelet-derived lambda-
gtll expression library." Blood 73,1498-1503. 
Zhan,X. ,B. Botes,X. Hu and M. Goldfarb. (1988). "The human 
FGF-5 gene encodes a novel protein related to fibroblast 
growth factors." Mol. Cell BioI. 8,3487-3495. 
